[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112203
1. Jong WH, Burger MC, Verheijen MA, Geertsma RE: Detection of the Presence of Gold Nanoparticles in Organs by Transmission Electron Microscopy. Materials (Basel); 2010 Sep 27;3(9):4681-4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the liver and spleen of animals treated with 10 nm gold nanoparticles, groups of nanoparticles were observed that could be positively identified by Energy Dispersive X-ray (EDX) analysis to contain gold, while nanoparticles could not be detected in the heart, kidney and brain.
  • In a number of samples, several globular structures of approximately the expected size were found in liver cells and the endothelium of blood vessels in the brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Angew Chem Int Ed Engl. 2007;46(30):5754-6 [17591736.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Environ Sci Technol. 2006 Jul 15;40(14):4353-9 [16903270.001]
  • [Cites] Biomaterials. 2008 Apr;29(12):1912-9 [18242692.001]
  • [Cites] J Control Release. 2009 Oct 1;139(1):81-4 [19538994.001]
  • [Cites] Part Fibre Toxicol. 2007 Oct 19;4:10 [17949501.001]
  • [Cites] Nanomedicine. 2009 Jun;5(2):162-9 [19217434.001]
  • [Cites] J Pharm Sci. 1995 Apr;84(4):493-8 [7629743.001]
  • [Cites] Biomaterials. 1999 Jul;20(14):1269-75 [10403044.001]
  • [Cites] J Control Release. 2006 Sep 12;114(3):343-7 [16876898.001]
  • (PMID = 28883347.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; gold nanoparticles / tissue distribution / transmission electron microscopy
  •  go-up   go-down


2. Živná H, Živný P, Palička V, Šimáková E, Řeháček V: The Influence of Repeated Blood Withdrawals before Surgery on Clinical Outcome. Acta Medica (Hradec Kralove); 2007;50(2):129-133
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver DNA synthesis (3H-thymidin - kBq/mg DNA) was performed.
  • FE-w had a higher (2.36±0.36) liver DNA synthesis after PH vs. SLD (1.21±0.49).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28949913.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Blood donor / Elective surgery / Iron / Preconditioning / Rat / Respiratory burst
  •  go-up   go-down


3. Servin-Abad L, Schiff ER: The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process. Gastroenterol Hepatol (N Y); 2006 Nov;2(11):819-825

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process.
  • Cirrhosis is considered an irreversible end stage of all liver diseases.
  • Current knowledge indicates that fibrosis is part of the liver repair process, which is dynamic.
  • The diagnosis of cirrhosis is currently established by liver biopsy and in most advanced cases can be confirmed by imaging.
  • Liver biopsy remains the gold standard but has several limitations: sampling error, size of the biopsy, and both inter- and intra-observer inconsistencies.
  • There are several cases of reversal of cirrhosis reported in association with different liver diseases.
  • The resolution of fibrosis in the majority of these diseases is related to successful treatment of the underlying etiology (eg, hepatitis B, hepatitis C, iron overload, Wilson disease, alcohol abstinence, metabolic syndrome in fatty liver disease, and decompression of biliary obstruction).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Apr;128(4):882-90 [15825072.001]
  • [Cites] Am J Med Sci. 1962 Nov;244:575-86 [14015706.001]
  • [Cites] Kumamoto Med J. 1964 Jun 30;17:67-78 [14289836.001]
  • [Cites] J Pediatr. 1975 Dec;87(6 Pt 2):1161-70 [1185415.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Hepatology. 1983 Nov-Dec;3(6):928-31 [6629323.001]
  • [Cites] Gastroenterology. 1979 Sep;77(3):532-6 [378754.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002148 [15846629.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1995 Jan;20(1):28-35 [7884615.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):400-7 [10419922.001]
  • [Cites] Histopathology. 1988 Dec;13(6):593-603 [2466750.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1709-13 [3287167.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1599-607 [11079009.001]
  • [Cites] Surgery. 2004 Jan;135(1):48-58 [14694300.001]
  • [Cites] Am J Physiol. 1990 Feb;258(2 Pt 2):H460-5 [2309911.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1859-60 [15330929.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD002148 [11687017.001]
  • [Cites] Australas Ann Med. 1970 Feb;19(1):54-7 [5505522.001]
  • [Cites] Pediatrics. 1970 Feb;45(2):260-8 [5413388.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:183-213 [232753.001]
  • [Cites] Gastroenterology. 1965 Dec;49(6):667-71 [5846420.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2573-6 [9881484.001]
  • [Cites] Hepatology. 2004 Apr;39(4):915-23 [15057894.001]
  • [Cites] Gastrointest Endosc. 1996 Jun;43(6):568-71 [8781934.001]
  • [Cites] J Hepatol. 1994 Mar;20(3):364-9 [8014448.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1647-54 [15185306.001]
  • [Cites] Gut. 2001 Apr;48(4):548-57 [11247901.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S82-8 [16447275.001]
  • [Cites] Bull World Health Organ. 1977;55(4):521-40 [304393.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1184-93 [16250039.001]
  • [Cites] J Gastroenterol Hepatol. 2002 May;17(5):589-97 [12084034.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1449-57 [14647056.001]
  • [Cites] Ann Intern Med. 2002 May 7;136(9):667-72 [11992302.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):105-17 [12512035.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):167-70 [15712656.001]
  • [Cites] J Clin Invest. 1985 Nov;76(5):1904-12 [4056057.001]
  • [Cites] Ann Intern Med. 1997 May 1;126(9):682-8 [9139553.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S38-53 [12591185.001]
  • [Cites] Q J Med. 1976 Oct;45(180):611-23 [188063.001]
  • [Cites] Med Clin North Am. 1966 Nov;50(6):1579-90 [5339192.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S113-20 [16447288.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):981-5 [9412303.001]
  • [Cites] Ann Intern Med. 2000 Apr 4;132(7):517-24 [10744587.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1303-13 [11984517.001]
  • [Cites] Arch Pathol Lab Med. 1998 Apr;122(4):342-5 [9648903.001]
  • [Cites] Gastroenterology. 1988 Nov;95(5):1399-402 [2844622.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1740-9 [15188169.001]
  • (PMID = 28381952.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cirrhosis reversal / biliary obstruction / fibrosis regression / hepatitis / nonalcoholic steatohepatitis
  •  go-up   go-down


Advertisement
4. Teutonico A, Libutti P, Lomonte C, Basile C: Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis. NDT Plus; 2010 Jun;3(3):273-275

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The laboratory follow-up should include the monitoring of serum creatinine and muscle enzyme levels, blood CsA levels and liver function tests.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Anaesthesiol Scand. 2005 Jul;49(6):859-64 [15954972.001]
  • [Cites] Nephron. 1994;68(1):57-62 [7991041.001]
  • [Cites] Kidney Int Suppl. 1995 Dec;52:S63-9 [8587287.001]
  • [Cites] Int J Tissue React. 2005;27(3):107-10 [16372476.001]
  • [Cites] Drug Metab Dispos. 1997 Oct;25(10):1191-9 [9321523.001]
  • [Cites] Int J Cardiol. 2005 May 11;101(1):9-17 [15860377.001]
  • [Cites] Ann Pharmacother. 2002 Feb;36(2):288-95 [11847951.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413 [18425901.001]
  • [Cites] Transplantation. 1994 Jul 15;58(1):42-5 [8036706.001]
  • [Cites] Am J Kidney Dis. 1996 Nov;28(5):631-67 [9158202.001]
  • [Cites] JAMA. 2003 Apr 2;289(13):1681-90 [12672737.001]
  • [Cites] Curr Opin Pediatr. 2009 Aug;21(4):475-80 [19502982.001]
  • [Cites] J Nephrol. 2002 May-Jun;15(3):317-9 [12113605.001]
  • (PMID = 28657046.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; acute kidney injury / ciclosporin / myoglobinuria / simvastatin
  •  go-up   go-down


5. Suzuki T, Sakurai F, Nakamura SI, Kouyama E, Kawabata K, Kondoh M, Yagi K, Mizuguchi H: miR-122a-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy. Mol Ther; 2008 Oct;16(10):1719-1726

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, intratumorally injected Ad vectors are disseminated into the systemic circulation and efficiently transduce the liver, resulting in severe hepatotoxicity.
  • In order to overcome this problem, an Ad vector carrying a microRNA (miRNA)-regulated expression system was developed by inserting into the 3'-untranslated region (3'-UTR) of the expression cassette four tandem copies of sequences with perfect complementarity to miR-122a, which exhibits liver-specific expression.
  • Intratumoral injection of the Ad vector containing the miR-122a target sequences resulted in a 130- to 1,500-fold reduction in hepatic transgene products (without affecting the transgene expression in the tumor) when compared with those from a conventional Ad vector.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28189004.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Lam PY, Sia KC, Khong JH, Geest B, Lim KS, Ho IA, Wang GY, Miao L, Huynh H, Hui KM: An Efficient and Safe Herpes Simplex Virus Type 1 Amplicon Vector for Transcriptionally Targeted Therapy of Human Hepatocellular Carcinomas. Mol Ther; 2007 Jun;15(6):1129-1136
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hybrid promoter, which consists of four copies of the apolipoprotein E (ApoE) enhancer element inserted upstream of the human α1-antitrypsin(hAAT) promoter, induced an higher level of transcription than other liver-specific promoters such as alpha-fetoprotein (AFP) and albumin (Alb) promoter.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182922.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Maher MM, Mansour AH: Study of Chronic Hepatopathy in Patients With Sickle Cell Disease. Gastroenterology Res; 2009 Dec;2(6):338-343

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatic lesions in sickle cell disease were studied essentially in autopsy specimens.
  • We investigated chronic hepatopathy in living adults with sickle cell disease and report the clinical, biochemical, and hepatic histological findings in these patients.
  • Clinical and laboratory investigation including liver function tests, serological tests for viral hepatitis, autoimmune hepatitis, and abdominal ultrasonography were performed in all of the patients.
  • Liver biopsies were studied from 27 patients.
  • RESULTS: There was clinical evidence of jaundice in 123 (72.4%) patients, 118 (69.4%) patients had palpable liver, and 69% percent of the patients had elevated enzymes.
  • Moderate or marked liver siderosis was associated with the number of transfusions.
  • CONCLUSIONS: The clinical spectrum of sickle cell disease ranges from mild liver function test abnormalities to significant hepatic abnormalities with marked hyperbilirubinemia.
  • Multiple factors may contribute to the etiology of the liver disease, including ischemia, transfusion related viral hepatitis, iron overload, and gallstones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990203.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Chronic hepatopathy / Sickle cell disease
  •  go-up   go-down


8. Patel K, Rockey DC: Clinical Utility of Biomarkers of Liver Fibrosis. Gastroenterol Hepatol (N Y); 2006 Jan;2(1):48-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Utility of Biomarkers of Liver Fibrosis.
  • : Hepatic fibrogenesis is a dynamic process and reflects a balance between matrix synthesis and degradation.
  • An accurate determination of hepatic fibrosis in chronic liver disease is important in determining prognosis, therapy outcomes, and disease progression.
  • Needle liver biopsy is an invasive procedure that is associated with small sample size and inaccurate staging, and provides only a semiquantitative assessment of fibrosis.
  • A number of simple and specific extracellular matrix biochemical markers predictive of fibrosis have been developed and validated in patients with chronic liver disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):659-65 [12825876.001]
  • [Cites] Clin Chem. 2004 Aug;50(8):1344-55 [15192028.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Aug;15(8):945-51 [11022838.001]
  • [Cites] J Viral Hepat. 2002 Nov;9(6):443-9 [12431207.001]
  • [Cites] Clin Chem. 2005 Feb;51(2):328-35 [15590748.001]
  • [Cites] Hepatology. 2003 Aug;38(2):481-92 [12883493.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1609-16 [9352863.001]
  • [Cites] Control Clin Trials. 2004 Oct;25(5):472-92 [15465617.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):61-8 [9654535.001]
  • [Cites] J Hepatol. 1999 Mar;30(3):472-8 [10190731.001]
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):712-8 [11068544.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1696-700 [11514405.001]
  • [Cites] Ann Med. 1996 Jun;28(3):241-53 [8811168.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Hepatology. 2004 Mar;39(3):862-3; author reply 863 [14999708.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):179-86 [12873813.001]
  • [Cites] Clin Chem. 1996 Apr;42(4):558-63 [8605673.001]
  • [Cites] Hepatology. 2005 Feb;41(2):257-64 [15660389.001]
  • [Cites] Comp Hepatol. 2004 Sep 23;3(1):8 [15387887.001]
  • [Cites] NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46 [14768714.001]
  • [Cites] Liver. 1999 Jun;19(3):183-7 [10395036.001]
  • [Cites] Liver. 1985 Jun;5(3):178-81 [4046756.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] J Viral Hepat. 1997 May;4(3):199-208 [9181529.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92 (11):2054-8 [9362191.001]
  • [Cites] Gastroenterology. 1988 Aug;95(2):487-9 [3292338.001]
  • [Cites] AIDS. 2003 Mar 28;17(5):721-5 [12646795.001]
  • [Cites] Hepatology. 2003 May;37(5):1222; author reply 1222-3 [12717404.001]
  • [Cites] Pathol Res Pract. 1999;195(11):727-31 [10605691.001]
  • [Cites] Lancet. 1986 Mar 8;1(8480):523-5 [2869260.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2004 Dec;41(6):935-42 [15582126.001]
  • [Cites] J Hepatol. 2003 Sep;39(3):326-32 [12927917.001]
  • [Cites] Hepatology. 2003 May;37(5):1220-1; author reply 1221 [12717403.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Gastrointest Endosc. 1996 Jun;43(6):568-71 [8781934.001]
  • [Cites] Dig Dis Sci. 1983 Jan;28(1):39-43 [6217961.001]
  • [Cites] Hepatol Res. 2003 Jan;25(1):22-31 [12644035.001]
  • [Cites] J Hepatol. 2000 Mar;32(3):447-52 [10735615.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):95-107 [15704042.001]
  • [Cites] Intern Med. 1998 Jul;37(7):568-75 [9711881.001]
  • [Cites] Semin Liver Dis. 2000;20(1):47-55 [10895431.001]
  • [Cites] Hepatology. 1994 Mar;19(3):635-40 [8119688.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jul;11(7):646-51 [8840240.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1397-402 [1672859.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Mar;18(3):253-7 [12603524.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1449-57 [14647056.001]
  • [Cites] Hum Pathol. 2001 Dec;32(12):1356-62 [11774169.001]
  • [Cites] Clin Liver Dis. 2000 May;4(2):319-55 [11232195.001]
  • [Cites] Hepatology. 2000 Sep;32(3):477-81 [10960438.001]
  • [Cites] Hepatology. 2004 May;39(5):1239-47 [15122752.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Dig Dis Sci. 1994 Nov;39(11):2426-32 [7525168.001]
  • [Cites] Arch Intern Med. 2003 Jan 27;163(2):218-24 [12546613.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Sep;16(9):1015-21 [11595066.001]
  • [Cites] Arch Intern Med. 1979 Jun;139(6):667-9 [443970.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S161-72 [12407590.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):57S-61S [9305665.001]
  • [Cites] Ann Intern Med. 2000 Nov 7;133(9):665-75 [11074899.001]
  • [Cites] J Viral Hepat. 2002 Mar;9(2):128-33 [11876795.001]
  • [Cites] Hepatology. 1994 Jul;20(1 Pt 1):15-20 [8020885.001]
  • [Cites] Nat Med. 2004 Apr;10(4):429-34 [15152612.001]
  • [Cites] Hepatology. 2005 Jan;41(1):48-54 [15690481.001]
  • [Cites] J Hepatol. 2001 Jul;35(1):120-6 [11495029.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B303-20 [12180305.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1303-13 [11984517.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):386-90 [10824882.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):103-6 [618417.001]
  • [Cites] Am J Gastroenterol. 2004 Jun;99(6):1160-74 [15180741.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1704-13 [15578508.001]
  • (PMID = 28210197.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Noninvasive / biopsy / extracellular matrix / fibrogenesis / serum markers
  •  go-up   go-down


9. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, van Rooijen NV, Busson P, Bastianutto C, Liu FF: Imaging the Modulation of Adenoviral Kinetics and Biodistribution for Cancer Gene Therapy. Mol Ther; 2007 May;15(5):921-929

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bioluminescence imaging (BLI) was conducted on tumor-bearing severe combined immunodeficient (SCID) mice (C666-1, EBV-positive human nasopharyngeal cancer) treated intravenously (i.v.) with 3 × 10<sup>8</sup> infectious units (ifu) of the adenoviral vectors.
  • At 72 hours, adv.oriPluc demonstrated an 8.4-fold higher tumor signal than adv.SV40luc; adv.oriP.E1A.oriP.luc was 26.7-fold higher; however, a significant liver signal was also observed, necessitating further action to improve biodistribution.
  • STI571 achieved the highest increase in tumor-to-liver ratio (TLR; 6.6-fold), which was associated with a 59% reduction in tumor interstitial fluid pressure (IFP) along with a decrease in platelet-derived growth factor-β receptor (PDGFβR) activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182894.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Larocque M, Syme A, Fallone BG: Sci-Sat AM(1): Imaging-01: Tumour and normal tissue T2 and ADC distributions for a mouse model at 9.4T. Med Phys; 2008 Jul;35(7Part3):3414
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sci-Sat AM(1): Imaging-01: Tumour and normal tissue T2 and ADC distributions for a mouse model at 9.4T.
  • We are currently using mouse models of human glioblastoma multiforme (GBM) to study tumour response to ionizing radiation by MRI at 9.4T.
  • Utilizing conventional imaging techniques coupled with quantitative measurements of transverse relaxation time (T2) and apparent diffusion coefficient (ADC), we monitor changes during tumour growth and subsequent changes after single-fraction radiotherapy.
  • In addition to tumour parameters, we have measured T2 and ADC in other structures that appear in the same transverse slices as tumour tissue.
  • Here we report the measured distributions of T2 and ADC in tumour and in normal tissues that are likely to be encountered during MR imaging of tumour xenografts in mice, including liver, kidney, fat, skeletal muscle, spinal cord, and brain.
  • Knowledge of parameter distributions in tumour is important because recent studies have suggested that the T2 and ADC responses after therapy may be the result of large shifts in smaller isolated pockets of tumour, rather than more moderate shifts in T2 and ADC over the whole tumour volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512910.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Diffusion / Ionizing radiation / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Relaxation times / Time measurement / Tissues
  •  go-up   go-down


11. Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M: Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Ann Med; 2006;38(8):592-604
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CFHR1 and CFHR3 transcripts are abundant in liver, but undetectable in the ocular retinal pigmented epithelium/choroid complex.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28950782.001).
  • [ISSN] 1365-2060
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Age‐related macular degeneration / alternative pathway / complement / deletion / evolution / factor H / factor H‐related / haplotype / vision
  •  go-up   go-down


12. Bumcrot D, Toudjarska I, Judge A, Brodsky J, Ambegia E, Buck T, Racie T, Jeffs L, MacLachlan I, Gollob J, Sah DW: Advancement to the clinic of an RNAi therapeutic for solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advancement to the clinic of an RNAi therapeutic for solid tumors.
  • : 3585 Background: Malignancies of the liver, including primary (hepatocellular carcinoma) and secondary (metastatic) tumors, represent a significant unmet medical need.
  • We are developing a therapeutic for solid tumors involving the liver that is comprised of lipid particle-formulated short interfering RNAs (siRNAs) targeting VEGF and the mitotic kinesin, KSP (Eg5).
  • Efficacy was demonstrated in a mouse liver tumor model.
  • METHODS: To assess efficacy in vivo, a stable nucleic acid lipid particle (SNALP) formulation was developed based on similar formulations previously shown to silence liver-expressed genes via systemic administration in multiple species.
  • A SNALP-formulated combination of the KSP and VEGF siRNAs (referred to as ALN-VSP01) was tested in an orthotopic liver tumor model in which human hepatoma cells (Hep3B) are implanted directly into the livers of immunocompromised mice.
  • RESULTS: Intravenous administration of ALN-VSP01 leads to dose-dependent inhibition of both KSP and VEGF expression in established liver tumors.
  • This was accompanied by the formation of numerous aberrant mitotic figures ("monoasters") in tumor cells indicative of the pharmacologic inhibition of KSP.
  • In addition, tumor growth was significantly inhibited by a course of ALN-VSP01 treatment, and ALN-VSP01 treatment provided a clear survival benefit even when treatment was initiated in animals with a significant tumor burden.
  • CONCLUSIONS: Systemic administration of ALN-VSP01 exhibited clear efficacy in a mouse orthotopic liver tumor model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Strom SC, Bruzzone P, Cai H, Ellis E, Lehmann T, Mitamura K, Miki T: Hepatocyte Transplantation: Clinical Experience and Potential for Future Use. Cell Transplant; 2006 Jan;15(1_suppl):105-110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocyte transplantation has been proposed as a method to support patients with liver insufficiency.
  • 1) for temporary metabolic support of patients in end-stage liver failure awaiting whole organ transplantation, 2) as a method to support liver function and facilitate regeneration of the native liver in cases of fulminant hepatic failure, and 3) in a manner similar to gene therapy, as a "cellular therapy" for patients with genetic defects in vital liver functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863760.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Clinical experience / Future use / Hepatocyte transplantation
  •  go-up   go-down


14. Schäfer R, Ayturan M, Bantleon R, Kehlbach R, Pintaske J, Conrad S, Wolburg H, Wiskirchen J, Weissert R: The Use of Clinically Approved Small Particles of Iron Oxide (SPIO) for Labeling of Mesenchymal Stem Cells Aggravates Clinical Symptoms in Experimental Autoimmune Encephalomyelitis and Influences Their In Vivo Distribution. Cell Transplant; 2008 Aug;17(8):923-941

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After transplantation labeled and nonlabeled MSC were detected in the CNS and the liver with significantly more SPIO-labeled cells present in the CNS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871886.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Experimental autoimmune encephalomyelitis / Homing / Imaging / Mesenchymal stem cells / Multiple sclerosis / Small particles of iron oxide
  •  go-up   go-down


15. Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M: In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery. Mol Ther; 2005 Mar;11(3):399-408

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, the integrase system was used to transfer the fumarylacetoacetate hydrolase (FAH) gene into the liver of mice affected with hereditary tyrosinemia type 1.
  • The increased frequency of these abnormal cells correlated with the amount of integrase plasmid administered, suggesting some form of integrase toxicity in Fah<sup>-/-</sup> livers.
  • The abnormal hepatocyte appearance was transient and livers analyzed after longer selection (90 days) showed 60% repopulation with only normal healthy FAH<sup>+</sup> hepatocytes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2004 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28192681.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; genetic disease / nonviral somatic gene therapy / phage integrase
  •  go-up   go-down


16. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR, Butler JS, Qin L, Racie T, Sprague A, Fava E, Zeigerer A, Hope MJ, Zerial M, Sah DW, Fitzgerald K, Tracy MA, Manoharan M, Koteliansky V, Fougerolles A, Maier MA: Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. Mol Ther; 2010 Jul;18(7):1357-1364

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both apoE-based endogenous and GalNAc-based exogenous targeting appear to be highly effective strategies for the delivery of iLNPs to liver.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178448.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Han B, Shen J, Gao Z: Treatment guided by ERCC1, RRM1, and BRCA1 protein expression in patients with advanced-stage NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):e19094

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligibility: Main inclusion criteria: Stage IV or stage IIIB NSCLC; Eastern Cooperative Oncology Group(ECOG) performance status (PS) 0-1; Measurable disease; Adequate bone marrow, kidney, liver function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962246.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lakey JRT, Kin T, Warnock GL, Shapiro AMJ, Tsapogas P, Imes S, Korbutt GS, Kneteman NM, Rajotte RV, Ryan EA: Long-Term Graft Function after Allogeneic Islet Transplantation. Cell Transplant; 2007 Apr;16(4):441-446

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total islet mass of 9,866 and 15,061 islet equivalents/kg body weight, respectively, was transplanted into the liver through portal vein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28858603.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immunosuppression / Islet transplantation / Long-term function / Simultaneous islet–kidney transplantation / Type 1 diabetes
  •  go-up   go-down


19. Mancosu P, Sghedoni R, Bettinardi V, Aquilina MA, Navarria P, Cattaneo GM, Di Muzio N, Cozzi L, Scorsetti M: Semiautomatic technique for defining the internal gross tumor volume of lung tumors close to liver/spleen cupola by 4D-CTa). Med Phys; 2010 Sep;37(9):4572-4576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semiautomatic technique for defining the internal gross tumor volume of lung tumors close to liver/spleen cupola by 4D-CTa).
  • PURPOSE: It has been shown that in cases of lung tumors close to the liver cupola, the four dimensional (4D)-CT postprocessing maximum intensity projection (MIP) algorithm does not fully recover the radiotherapy internal gross tumor volume (IGTV).
  • CONCLUSIONS: A semiautomatic technique to include the residual part of IGTV covered by liver/spleen cupola when using MIP algorithm was validated on phantom and on selected patients, revealing the possibility of defining the IGTV for patients with lesions located near liver/spleen cupola by performing only the contours on the MIP series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524578.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Germanium / Liver / Lungs / Medical imaging / Medical radiation safety / Radiation therapy / Radiation therapy equipment / Tissues / Treatment planning / computerised tomography / internal gross tumor volume-IGTV / internal target volume-ITV / liver / lung / lung node, radiotherapy-RT / maximum intensity projection-MIP / medical image processing / phantoms / radiation therapy / tumours
  •  go-up   go-down


20. Tiker F, Gürakan B, Tarcan A: Relationship between serum bilirubin and coagulation test results in 1-month-old infants. Indian J Pediatr; 2005 Mar;72(3):205-207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Although the connection between cholestasis and conjugated hyperbilirubinemia is well known, mild hepatic dysfunction or cholestasis may also be associated with unconjugated hyperbilirubinemia in some infants with prolonged jaundice.
  • However, a significant positive correlation between bilirubin levels and PT and APTT suggest that a higher bilirubin load to the liver may cause some degree of vitamin K deficiency due to mild cholestasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr. 2000 Jun;89(6):694-7 [10914965.001]
  • [Cites] Thromb Haemost. 1999 Mar;81(3):456-61 [10102477.001]
  • [Cites] J Pediatr. 1984 Dec;105(6):943-5 [6502345.001]
  • [Cites] Eur J Pediatr. 1985 May;144(1):37-40 [4018100.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1985 Oct;4(5):741-5 [4045632.001]
  • [Cites] J Paediatr Child Health. 1993 Jun;29(3):177-81 [8517996.001]
  • [Cites] Acta Paediatr Suppl. 1999 Aug;88(430):95-103 [10569231.001]
  • [Cites] Semin Perinatol. 1997 Feb;21(1):70-85 [9190036.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):430-7 [10086774.001]
  • [Cites] Eur J Pediatr. 1991 Mar;150(5):310-3 [1675170.001]
  • (PMID = 28378167.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Cholestasis / Coagulation / Prolonged unconjugated hyperbilirubinemia / Vitamin K deficiency
  •  go-up   go-down


21. Amer R, Bamonte G, Forrester JV: Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency. Eur J Ophthalmol; 2007 Jul-Aug;17:666-668

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver biopsy disclosed granulomatous hepatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221566.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Metcalf JA, Ma X, Linders B, Wu S, Schambach A, Ohlemiller KK, Kovacs A, Bigg M, He L, Tollefsen DM, Ponder KP: A Self-inactivating γ-Retroviral Vector Reduces Manifestations of Mucopolysaccharidosis I in Mice. Mol Ther; 2010 Feb;18(2):334-342

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report demonstrates that intravenous (i.v.) injection of a SIN γ-RV expressing canine IDUA from the liver-specific human α<sub>1</sub>-antitrypsin promoter into adult or newborn MPS I mice completely prevents biochemical abnormalities in several organs, and improved bone disease, vision, hearing, and aorta to a similar extent as was seen with administration of the LTR-intact vector to adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182939.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Grinshpun A, Condiotti R, N Waddington S, Peer M, Zeig E, Peretz S, Simerzin A, Chou J, Pann CJ, Giladi H, Galun E: Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus-based Vector. Mol Ther; 2010 Sep;18(9):1592-1598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we have shown that these vectors are capable of integrating stably into hepatocyte cell lines and adult murine livers and lead to long-term transgene expression.
  • However, a double neonatal administration protocol led to normalized blood glucose levels, significantly extended survival, improved body weight, and decreased accumulation of liver glycogen associated with the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178467.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Atassi Z, Varga D, Plotzki K, Kurzeder C, Kreienberg R: Peritoneal metastases in breast cancer patients: Differences in survival depending on histological subtype. J Clin Oncol; 2009 May 20;27(15_suppl):e12024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e12024 Background: Distant spread from breast cancer is commonly found in bones, lungs, liver, and central nervous system.
  • 30 (68%) patients had endocrine responsive tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964300.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Rodgers J, Murray C, Leaves N: Comparison of three methods to detect mutations in the PI3K oncogene in FFPE cancer samples. J Clin Oncol; 2009 May 20;27(15_suppl):e22212

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating mutations in exons 9 and 20 of the PI3KCA oncogene have been observed in a number of important cancer types including: gastrointestinal, breast, liver, lung and genito-urinary cancers.
  • METHODS: Source BioScience (Nottingham, UK) tested three different methods for the detection of PI3K mutations in archival tumour samples, in their CPA and GLP accredited laboratories.
  • Tumour content was evaluated by pathology review.
  • The DxS test had a high degree of sensitivity provided there was more than 20% tumour content in the test sample as determined by histology and pathology review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hoekstra R, Deurholt T, Ten Bloemendaal L, Desille M, van Wijk ACWA, Clement B, Oude Elferink RPJ, van Gulik TM, Chamuleau RAFM: Assessment of in Vitro Applicability of Reversibly Immortalized NKNT-3 Cells and Clonal Derivatives. Cell Transplant; 2006 May;15(5):423-433

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro applications of human hepatocytes, such as bioartificial livers and toxicity assays, require thoroughly testing of human cell lines prior to using them as alternative cell sources.
  • Low-passage (P2) and high-passage (P28) NKNT-3 cells and clonal derivatives were characterized for reversion of immortalization, heterogeneity, and hepatic functionality.
  • The mRNA levels of genes related with hepatic differentiation increased 4-20-fold after reversion.
  • However, the levels never exceeded 0.1% of that detected in liver and no urea production nor ammonia elimination was detected.
  • These findings emphasize that in vivo testing of hepatic cell lines is little informative for predicting their value for in vitro applications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871867.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Hepatocyte / Immortalization / Liver / SV40 large T antigen / Telomerase
  •  go-up   go-down


27. Morsi MI, Hussein AE, Mostafa M, El-Abd E, Abd El-Moneim NA: Evaluation of tumour necrosis factor-α, soluble P-selectin, γ-glutamyl transferase, glutathione S-transferase-π and α-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci; 2006 Jan;63(2):74-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of tumour necrosis factor-α, soluble P-selectin, γ-glutamyl transferase, glutathione S-transferase-π and α-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy.
  • To evaluate the significance of tumour necrosis factor-α (TNF-α), sP-selectin, γ-glutamyl transferase (GGT), glutathione S-transferase-π (GST) and α-fetoprotein (AFP) in the diagnosis and follow up of HCC patients during chemotherapy with adriamycin, 45 subjects (15 healthy volunteers, 15 with benign liver diseases and 15 HCC patients) are studied before and during chemotherapy (three cycles of intravenous adriamycin).
  • Serum levels of GGT and GST were significantly higher in HCC patients with poorly differentiated tumours than in patients with well- and moderately differentiated tumours.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28705134.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hepatitis B virus / Hepatitis C virus / Hepatocellular carcinoma / Neoplasms, liver
  •  go-up   go-down


28. Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GB, de Kimpe S, Ferlini A, Aartsma-Rus A, van Deutekom JC: Preclinical PK and PD Studies on 2'-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model. Mol Ther; 2010 Jun;18(6):1210-1217

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After i.v. administration, the oligonucleotide peak levels in plasma, liver, and kidney were higher than after s.c. or i.p. injections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178497.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Eugene Redmond D Jr, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ: Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Mol Ther; 2008 Jul;16(7):1252-1260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further, chimeric-1829 demonstrates altered tropism in rodent skeletal muscle, liver, and brain including nonhuman primates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178482.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Di Battista M, Saponara M, Pantaleo MA, Catena F, Santini D, Lolli C, Di Scioscio V, Astorino M, Maleddu A, Nannini M, Biasco G: Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients.
  • The prognosis is strongly correlated with both tumor size and mitotic index.
  • The most common sites of tumor origin were the stomach (54.9%) and the small bowel (36.9%).
  • Sites of tumor metastasis were liver (18.2%), peritoneum (36.4%) or both (19.3%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • Approximately 6 weeks after completion of chemo radiation, evaluation was performed regarding tumour response and resectability.
  • Out of 8 patients who underwent radical surgical resection, only one patient developed local recurrence and simultaneous liver metastasis during the follow up period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Huang KW, Huang YC, Tai KF, Chen BH, Lee PH, Hwang LH: Dual Therapeutic Effects of Interferon-α Gene Therapy in a Rat Hepatocellular Carcinoma Model With Liver Cirrhosis. Mol Ther; 2008 Oct;16(10):1681-1687
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual Therapeutic Effects of Interferon-α Gene Therapy in a Rat Hepatocellular Carcinoma Model With Liver Cirrhosis.
  • : Human hepatocellular carcinoma (HCC) often arises from a background of liver cirrhosis.
  • Therefore, in order to develop therapeutic strategies for HCC, an animal model bearing multifocal liver tumors accompanied by liver cirrhosis is a preferred experimental setting.
  • By adjusting the duration of administration of DEN, the animals could be induced to develop HCC alone, or HCC and liver cirrhosis simultaneously.
  • Our results demonstrated that targeting of IFN-α expression to the liver significantly reduced liver tumor volume and ameliorated liver cirrhosis.
  • Mechanistic studies revealed that IFN-α gene therapy induced immunomodulatory, antiproliferative, and proapoptotic activities that were effective in the control of tumor growth, and reduced the expressions of transforming growth factor-β (TGF-β) and tissue inhibitor of metalloproteinase-1 (TIMP-1), leading to amelioration of liver cirrhosis.
  • These results suggest that IFN-α gene therapy is a promising strategy to treat HCC patients who have concomitant liver cirrhosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28189003.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Senkal M, Haaker R, Linseisen J, Wolfram G, Homann HH, Stehle P: Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue. JPEN J Parenter Enteral Nutr; 2005;29(4):236-240

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue.
  • BACKGROUND: The uptake of ω-3 polyunsaturated fatty acids (PUFAs) into the liver, gut mucosa, and tumor tissue and plasma levels after preoperative administration of supplemented enteral nutrition was investigated in patients with malignancies of the upper gastrointestinal tract.
  • Tissue samples of liver, gut mucosa (small intestine), and tumor were taken during surgery and homogenized.
  • As compared with the control group, the PUFA group had significantly increased levels of EPA in liver tissue (0.4 vs 1.3 weight %), gut mucosa (0.3 vs 1.0 weight %), and tumor tissue (0.3 vs 0.8 weight %).
  • Also, the DHA levels in the PUFA group were significantly higher than the control group: liver tissue (4.1 vs 7.5 weight %), gut mucosa (2.1 vs 3.7 weight %) and tumor tissue (1.9 vs 4.2 weight %).
  • CONCLUSIONS: This study suggests that administration of PUFA-enriched diets leads to increased incorporation of EPA and DHA not only in liver and gut mucosa tissue, but also in tumor tissue in patients with solid gastrointestinal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28052736.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Koenig S, Krause P, Hosseini ASA, Dullin C, Rave-Fraenk M, Kimmina S, Entwistle AL, Hermann RM, Hess CF, Becker H, Christiansen H: Noninvasive Imaging of Liver Repopulation following Hepatocyte Transplantation. Cell Transplant; 2009 Jan;18(1):69-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive Imaging of Liver Repopulation following Hepatocyte Transplantation.
  • We recently demonstrated liver irradiation under the additional stimulus of partial hepatectomy as being an effective primer in the rat liver repopulation model based on hepatocyte transplantation.
  • Livers of dipeptidylpeptidase IV (DPPIV)-deficient rats were preconditioned with irradiation.
  • Four days later, a partial hepatectomy was performed and wild-type (DPPIV<sup>+</sup>) hepatocytes were transplanted into recipient livers via the spleen.
  • Optical imaging detected Cy5.5-specific fluorescence in the liver region of the transplanted animals, increasing in intensity with time, representing extensive host liver repopulation within 16 weeks following transplantation.
  • Comparison with ex vivo immunofluorescence staining of liver sections confirmed the optical imaging results.
  • Optical imaging constitutes a potent method of assessing the longitudinal kinetics of liver repopulation in the rat transplantation model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28841347.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; DPPIV / In vivo optical imaging / Irradiation / Near infrared dye Cy5.5 / Rat liver repopulation
  •  go-up   go-down


35. Morris E, Thomas J, Forman D, Quirke P, Cottier B, Poston GJ: The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases.
  • : 4099 Background: AJCC V.6 (2002) places all patients with MCRC beyond the lymph node basin of the primary tumor in a homogenous Stage 4.
  • Patients with inoperable hepatic MCRC can be made operable with curative intent with chemotherapy yet remaining in Stage 4.
  • Survival was calculated from the date of resection of each patient's primary colorectal tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yue J, Yu J, Li S, Yin Y, Liu T, Zhu J, Lu J: PhaseI/II clinical trial of dose escalation using daily on-line cone beam CT guided radiotherapy combined with active breath control after transcatheter arterial chemoembolization for hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15654

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous study demonstrated that lipiodol can be a reliable surrogate of direct tumor targeting in Kv- cone beam CT(CBCT) for patients with good lipiodol embolization.
  • By reducing geometric position uncertainty, as well as liver movement, the technique of ABC combined with on-line CBCT guidance can permit CTV(clinical target volume)-PTV(planning target volume) margin reduction and dose escalation.
  • The purpose of the study is to apply the new technique for clinical application and investigate the dose escalation, toxicities and response of liver tumors with the technique combined with chemoembolization(TACE).
  • METHODS: 20 HCC patients with Child-Pugh A liver function score were treated by daily on-line CBCT guided radiotherapy relying on lipiodol combined with ABC after TACE.
  • Each mean liver dose not reached 23G y, V30 ( the percentage of normal liver volume with radiation dose≥30 Gy) less than 28%.
  • None of these patients developed Grade 2 or greater liver toxicity except two patients developed Grade 2 gastrointestinal complications and one had grade 1 acute liver toxicity.The overall immediate tumor response rate was 76.3%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Chi Z, Cui C, Yuan X, Si L, Sheng X, Shen L, Guo J: Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):e20014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study.
  • : e20014 Background: To investigate the efficacy and safety of hepatic intra-arterial infusion of cisplatin, fotemustine combined with systemic dacarbazine for the treatment of melanoma patients with liver metastasis.
  • METHODS: From 2005.7 to 2008.7, thirty-six melanoma patients with liver metastatic were enrolled.
  • Systemic dacarbazine (250mg/m<sup>2</sup> d1-5) and intra-arterial hepatic (i.a.h.) of cisplatin (75mg/m<sup>2</sup> d6) and fotemustine (100mg/m<sup>2</sup> d7) were given repeated for 4-weeks.
  • CONCLUSIONS: Intra-arterial hepatic chemotherapy show its efficacy and may prolong PFS in melanoma patients with liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Schilling G, Schuch G, Panse JP, Sterneck M, Bokemeyer C: Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report.
  • : e21527 Background: HEH is a rare tumor of the liver with an unpredictable malignant potential.
  • Surgical resection or liver transplantation is recommended in locally advanced disease and has been successfully performed in selected cases with extrahepatic manifestations.
  • CASE REPORT: A 33-year old caucasian previously healthy male was admitted to hospital with newly diagnosed suspicious lesions in liver and spleen.
  • Biopsy revealed a tumor with predominant epithelioid cells, positive for CD31 and CD34 and negative for CD117, HHV8, AFP and CEA, classified as a HEH.
  • Retrospective analysis after 9 cycles demonstrated stable disease in comparison to the recent investigation, but an overall progression of 22% according to RECIST criteria in the liver was observed.
  • Due to the excellent tolerance we increased the daily dose to 30 mg (21/28) and 6 months later a slight regression in the lung and overall stable disease in the liver was observed.
  • The patient was listed for liver transplantation and after another 4 months on lenalidomide 30 mg, he was successfully transplanted recently.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963457.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Aliberti C, Benea G, Tilli M, Fiorentini G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients.
  • A suspension of polyvinyl-alcohol beads (DC Bead) preloaded with Irinotecan ( 81 TACE procedures with 2ml of microspheres preloaded with 100mgr of Irinotecan and 104 with 4ml loaded with 200mgr of Irinotecan) was delivered selectively into hepatic arteries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Herrero A, Pulitano C, Dondero F, Dokmak S, Aussilhou B, Sauvanet A, Farges O, Faivre S, Belghiti J: Use of partial liver resection according to carcinologic procedures as an alternative to liver transplantation for HCC. J Clin Oncol; 2009 May 20;27(15_suppl):e15628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of partial liver resection according to carcinologic procedures as an alternative to liver transplantation for HCC.
  • : e15628 Background: There are some arguments showing that anatomic resection, anterior approach and preoperative transarterial chemoembolization (TACE) with portal vein embolization (PVE) before major resection improves long term survival after partial liver resection for HCC.
  • This oncologic approach could compete with liver transplantation (LT) which remains poorly accessible in western countries and inaccessible in the greatest part of the world.The aim of this study was to evaluate in patients with good liver function.the result of partial liver resection with an intended carcinologic approach.
  • METHODS: Between 1998 and 2007, among 210 patients resected for HCC, we selected a subgroup of 36 patients with single and small HCC (< 6 cm) developed on chronic liver disease (CLD) who underwent anatomic partial resection and anterior approach and TACE and PVE in case of major resection.
  • The mean size of the tumor was 5.2 cm and 86% (n=31) had major resection.
  • Tumor recurrence occurred in 16 cases( 44%) after a mean delay of 21 months (ranging from 5 to 58 months).
  • CONCLUSIONS: Partial liver resection for small tumors in patients with good liver function according to carcinologic procedures allow an excellent overall and disease free survival which can challenge LT.
  • In the case of single HCC <6cm on chronic liver disease, this surgical approach may therefore be considered as a valuable alternative to LT within a curative intent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962710.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Garufi C, Torsello A, Tumolo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Sperduti I, Pizzi G, Ettorre GM: POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol; 2009 May 20;27(15_suppl):e15020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM).
  • Aim of the study was to have at least 30% liver resection rate (power of 80% for p0=10% and p1=25%).
  • Primary tumor: colon/rectum 34/9, primary tumor resected 39 pts (79%), synchronous metastases: 35 pts (81%), liver <25%/25%: 9/34 ((21/79%); median CEA/CA19-9: 55 ng/ml (1-6,600)/91.8 U/L (2.66440); unresectability: (a): 9 (21%), (b):14 (33%), (c) 1, (d): 4 (9%), (e): 15 (35%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964412.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Brady S, Yoshizumi T, Toncheva G, Frush D: Implementation of radiochromic film dosimetry protocol for volumetric dose assessments to various organs during diagnostic CT procedures. Med Phys; 2010 Sep;37(9):4782-4792

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dose distributions are presented for the lungs, liver, and kidneys to demonstrate the organ volume dosimetry technique.
  • Similar comparisons within the anthropomorphic phantom also indicated a consistent difference, tracking along the low and high dose regions, for the lung (28%) (SD±8%) and liver and kidneys (15%) (SD±4%).
  • Once corrected, the average film response agreed to better than 3% (SD±2%) for the CTDI scans, and for the anthropomorphic phantom scans: 3% (SD±3%) for the lungs, 5% (SD±3%) for the liver, and 4% (SD±3%) for the kidneys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524581.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / CT dosimetry / Computed tomography / Computer software / Dosimetry / GafChromic XRQA / Kidneys / Liver / Lungs / Medical imaging / Radiochromic film / Standards and calibration / TLD dosimetry / Thermoluminescent dosimeters / Tissues / biological tissues / calibration / computerised tomography / dosimetry / kidney / liver / lung / phantoms / thermoluminescent dosimeters / two-dimensional dosimetry
  •  go-up   go-down


43. Stravitz RT: Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y); 2006 May;2(5):346-354

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist.
  • The referral of a patient with cirrhosis to a liver transplant center for evaluation is usually made by a local gastroenterologist.
  • The role of the referring gastroenterologist begins with early identification and modification of high-risk behaviors, which may delay listing a patient for liver transplantation.
  • The local gastroenterologist must also fully appreciate what constitutes a timely referral of a patient to a liver transplant center and the consequences of late referral.
  • Although patients experience the inevitable deterioration of their liver function, which in turn advances their priority on the liver transplant waiting list, the referring gastroenterologist must also anticipate medical complications of cirrhosis, and should initiate appropriate surveillance and prophylaxis programs to detect and prevent these complications.
  • Adherence to these guidelines will increase the probability that a patient with chronic liver failure will undergo successful liver transplantation and will decrease post-transplant morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003 Aug;39(2):208-14 [12873817.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1819-27 [14654322.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):51-8 [12480560.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):937-40 [12949737.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):234-41 [3297907.001]
  • [Cites] Hepatology. 1990 Aug;12(2):273-80 [2391068.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Hepatology. 1992 Jul;16(1):132-7 [1352268.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):435-9 [11866284.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1172-81 [9261620.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1171-4 [7557868.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] Scand J Gastroenterol. 1987 Jan;22(1):117-23 [3563404.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):266-72 [12586291.001]
  • [Cites] Liver Transpl. 2005 Mar;11(3):249-60 [15719412.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Liver Transpl. 2005 Jun;11(6):679-83 [15915490.001]
  • [Cites] Gut. 1982 Jan;23(1):1-7 [7035298.001]
  • [Cites] Drugs. 1995 Mar;49(3):467-84 [7774516.001]
  • [Cites] Hepatology. 1995 Sep;22(3):753-8 [7657279.001]
  • [Cites] J Hepatol. 1986;3(1):75-82 [3745889.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1407-32 [15880505.001]
  • [Cites] J Hepatol. 2005;42 Suppl(1):S65-74 [15777574.001]
  • [Cites] Liver Transpl. 2005 Feb;11(2):124-33 [15666386.001]
  • [Cites] Hepatology. 2004 Mar;39(3):841-56 [14999706.001]
  • [Cites] Hepatology. 2002 Jan;35(1):105-9 [11786965.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):645-63 [11565135.001]
  • [Cites] Hepatology. 2001 Jul;34(1):28-31 [11431730.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):941-66 [12949738.001]
  • [Cites] N Engl J Med. 1988 Oct 13;319(15):983-9 [3262200.001]
  • [Cites] Am J Transplant. 2003 Dec;3(12):1481-7 [14629278.001]
  • [Cites] Hepatology. 1997 Jan;25(1):63-70 [8985266.001]
  • [Cites] Gut. 1979 Feb;20(2):133-6 [311747.001]
  • [Cites] Liver Transpl. 2002 Jul;8(7):582-7 [12089709.001]
  • [Cites] Liver. 1999 Jun;19(3):188-92 [10395037.001]
  • [Cites] Miner Electrolyte Metab. 1993;19(6):362-7 [8164617.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Mar;28(3):468-79 [15084905.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Hepatology. 1994 Jan;19(1):72-9 [8276370.001]
  • [Cites] Ann Intern Med. 1989 May 15;110(10):838-9 [2712463.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):286-90 [9445408.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2268-74 [14572578.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):91-6 [12512033.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2193-7 [10445549.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):68-76 [15590870.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):716-24 [2210673.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):1968-76 [11467622.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):462-6 [11982728.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):665-76 [11565136.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1680-5 [1568578.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] Dig Dis Sci. 2001 Dec;46(12):2752-7 [11768269.001]
  • [Cites] Ann Intern Med. 1995 Apr 15;122(8):595-8 [7887554.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1005-14 [15057740.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):579-86 [9247479.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Ann Intern Med. 1970 Sep;73(3):393-6 [5455989.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2343-51 [11007240.001]
  • [Cites] Hepatology. 2004 Jul;40(1):65-72 [15239087.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):988-93 [10099140.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):414-9 [10419924.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112 [10564534.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Hepatology. 2004 Mar;39(3):739-45 [14999692.001]
  • [Cites] Gastroenterology. 1980 Mar;78(3):512-7 [7351289.001]
  • [Cites] Liver Transpl. 2000 Jul;6(4):440-2 [10915165.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):503-8 [10685758.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Hepatology. 1988 Jul-Aug;8(4):966-8 [3391524.001]
  • (PMID = 28289338.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cirrhosis / liver failure / liver transplantation / portal hypertension
  •  go-up   go-down


44. Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA: Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol; 2010 Oct;1(3):149-155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical management of the increasing burden of non-alcoholic fatty liver disease.
  • Obesity-induced liver disease (non-alcoholic fatty liver disease (NAFLD)) describes a spectrum from steatosis through steatohepatitis to cirrhosis.
  • Its prevalence is rising in tandem with societal rates of obesity which through consequent insulin resistance and fat deposition in hepatocytes lead to hepatocyte death and attempts at repair, which if persistent, lead to activation of liver fibrogenic cells.
  • NAFLD, which may also progress to primary liver cancer, is now the most common cause of chronic liver disease in affluent countries.
  • There is currently no single accurate diagnostic test besides a liver biopsy.
  • The decision to consider a liver biopsy will be informed by the presence of insulin resistance determined by comparatively easy-to-measure factors together with other putative markers of progression such as hypertension.
  • If a liver biopsy is performed, patients with steatosis with no evidence of inflammation may be less aggressively managed while those with steatohepatitis, since they have a faster trajectory to cirrhosis, should be managed more robustly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 2003;63(22):2379-94 [14609346.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1298-305 [15864349.001]
  • [Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]
  • [Cites] Semin Diagn Pathol. 2005 Nov;22(4):330-8 [16939061.001]
  • [Cites] Nat Med. 2000 Sep;6(9):998-1003 [10973319.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Rev Gastroenterol Disord. 2002;2(1):11-9 [12122975.001]
  • [Cites] Liver Int. 2007 Mar;27(2):215-9 [17311616.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1103-9 [7523217.001]
  • [Cites] Obes Res. 2005 Jul;13(7):1180-6 [16076987.001]
  • [Cites] Hepatology. 1995 Dec;22(6):1714-9 [7489979.001]
  • [Cites] Ann Intern Med. 2000 Jan 18;132(2):112-7 [10644271.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):284-92 [12901866.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):556-64 [17459514.001]
  • [Cites] Hepatology. 2004 Mar;39(3):770-8 [14999696.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):43-50 [12499321.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S39-43 [16540766.001]
  • [Cites] Gut. 2004 Mar;53(3):438-45 [14960531.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):960-7 [12809815.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):628-34 [17258346.001]
  • [Cites] Diabetes Care. 2001 Feb;24(2):412 [11213906.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1366-74 [17476695.001]
  • [Cites] J Hepatol. 2009 Jan;50(1):204-10 [19014878.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] Hepatology. 2005 Jul;42(1):44-52 [15895401.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8 [15225167.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Aviat Space Environ Med. 1984 Jan;55(1):59-61 [6696696.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Sep-Oct;7(5):469-72 [1391727.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):195-9 [11580141.001]
  • [Cites] J Hepatol. 2010 Jun;52(6):913-20 [20413174.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Obesity (Silver Spring). 2007 Sep;15(9):2190-9 [17890486.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):532-40 [19409898.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] J Clin Gastroenterol. 2002 Mar;34(3):255-62 [11873108.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):953-9 [9269832.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8 [15339742.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1101-7 [17661371.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):460-8 [14762783.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):311-8 [9453491.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]
  • [Cites] Hepatology. 2006 Oct;44(4):865-73 [17006923.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Semin Liver Dis. 2001;21(1):3-16 [11296695.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):200-8 [8907574.001]
  • [Cites] N Engl J Med. 2010 May 6;362(18):1675-85 [20427778.001]
  • [Cites] Clin Liver Dis. 2009 Nov;13(4):667-88 [19818312.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1048-58 [15625647.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):4-7 [18973842.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):745-50 [12198701.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1844-50 [11473047.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1316-20 [15233671.001]
  • [Cites] Curr Diab Rep. 2008 Apr;8(2):156-63 [18445359.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):519-25 [11232700.001]
  • [Cites] Eur J Radiol. 2008 May;66(2):313-20 [17646074.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):842-5 [9547102.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S40-8 [17486051.001]
  • [Cites] Hepatology. 2003 Sep;38(3):664-73 [12939593.001]
  • [Cites] Am J Clin Nutr. 2006 Jul;84(1):136-42; quiz 268-9 [16825687.001]
  • [Cites] Gut. 2008 May;57(5):649-54 [18276725.001]
  • [Cites] Dig Dis Sci. 1982 Mar;27(3):265-8 [6176409.001]
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3476-83 [18567074.001]
  • [Cites] Ann Hepatol. 2009;8 Suppl 1:S4-8 [19381118.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):742-55 [15765409.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):634-42 [15747110.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):71-9 [12512031.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Am J Med. 1999 Nov;107(5):450-5 [10569299.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1375-81 [17518368.001]
  • (PMID = 28839568.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


45. Stengel JZ, Harrison SA: Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment. Gastroenterol Hepatol (N Y); 2006 Jun;2(6):440-449

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.
  • Nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in our society and is the most common etiology for patients presenting with elevated liver enzymes.
  • Given the significant numbers of patients presenting with NAFLD, it is important to distinguish between simple fatty liver and nonalcoholic steatohepatitis (NASH).
  • Whereas simple fatty liver is thought to have a benign prognosis generally, NASH may progress to cirrhosis in a subset of patients.
  • Performance of liver biopsies in all NAFLD patients is not feasible but recent studies have identified several clinical factors that may predict the patients at greatest risk for NASH and advanced fibrosis, and thus biopsy procedures may be confined to the patients meeting these criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):368-73 [16454845.001]
  • [Cites] JAMA. 2003 Sep 24;290(12 ):1577; author reply 1578 [14506111.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):926-30 [12738478.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):91-100 [11438497.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1222-5 [15382153.001]
  • [Cites] Jpn J Med. 1988 May;27(2):142-9 [3047469.001]
  • [Cites] Nat Med. 2000 Sep;6(9):998-1003 [10973319.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1639-46 [15185305.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):801-4 [15365409.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1103-9 [7523217.001]
  • [Cites] Indian J Exp Biol. 2005 Feb;43(2):177-80 [15782820.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4293 [10566691.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):148-55 [11438504.001]
  • [Cites] Hepatology. 2004 Mar;39(3):770-8 [14999696.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1286-92 [12774006.001]
  • [Cites] Gut. 2004 Mar;53(3):413-9 [14960526.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1356-62 [10573511.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):375-8 [12105866.001]
  • [Cites] Proc Nutr Soc. 2003 Feb;62(1):201-6 [12749347.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):734-8 [10839868.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):829-39 [12297830.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1485-93 [12029634.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):623-8 [15352910.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1442-9 [7982643.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1496-500 [12094872.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):716-24 [11097478.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8 [15225167.001]
  • [Cites] Invest Radiol. 2000 May;35(5):319-24 [10803673.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):76-81 [14687145.001]
  • [Cites] Kidney Int. 2003 Aug;64(2):459-67 [12846741.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):103-7 [9252081.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Hepatology. 2004 Jan;39(1):188-96 [14752837.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2365-8 [15571584.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):32-8 [12480557.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):255-9 [15633226.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Gut. 2005 Jan;54(1):122-7 [15591516.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2711-7 [11569700.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10):1578-83 [15573908.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):311-8 [9453491.001]
  • [Cites] Trends Endocrinol Metab. 2004 Nov;15(9):425-31 [15519889.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3191-6 [15769987.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Clin Liver Dis. 2004 Nov;8(4):861-79, ix [15464659.001]
  • [Cites] Ann Intern Med. 2002 Apr 2;136(7):493-503 [11926784.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2485-90 [14638353.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):117-25 [12851877.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1513-7 [10323371.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1647-54 [15185306.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] J Hepatol. 1991 Mar;12(2):224-9 [2051001.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1008-17 [14512888.001]
  • [Cites] Immunology. 1994 Oct;83(2):262-7 [7835945.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1014-21 [1398481.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72 [11564008.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):745-50 [12198701.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Mar;34(1):91-104 [15823441.001]
  • [Cites] Obes Surg. 2003 Jun;13(3):347-9 [12841891.001]
  • [Cites] Hepatology. 1996 Jun;23(6):1464-7 [8675165.001]
  • [Cites] Circulation. 2003 Sep 30;108(13):1546-51 [14517150.001]
  • [Cites] Hepatology. 2002 Jul;36(1):142-9 [12085358.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Mar 1;19(5):537-44 [14987322.001]
  • [Cites] Hepatology. 2004 Oct;40(4):820-6 [15382171.001]
  • [Cites] Hepatol Res. 2001 Oct;21(2):147-158 [11551835.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):421-9 [10488699.001]
  • [Cites] Pharmacotherapy. 2000 Mar;20(3):270-9 [10730683.001]
  • [Cites] Atherosclerosis. 2004 Jan;172(1):127-33 [14709366.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Aug;28(8):1064-71 [15254487.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):931-9 [11910345.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2448-55 [11513189.001]
  • [Cites] J Appl Physiol (1985). 2003 Jun;94(6):2127-34 [12547845.001]
  • [Cites] J Womens Health (Larchmt). 2003 Mar;12 (2):115-22 [12737710.001]
  • [Cites] Gastroenterology. 1990 Nov;99(5):1408-13 [2210247.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1723-7 [12365955.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E906-16 [12959938.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1082-90 [15842582.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1072-81 [15842581.001]
  • [Cites] Am J Dig Dis. 1967 Feb;12(2):198-208 [6016689.001]
  • [Cites] Rom J Gastroenterol. 2003 Sep;12 (3):189-92 [14502318.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Diabetes. 2005 Mar;54(3):603-8 [15734833.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):745-50 [11584371.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 28316519.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Nonalcoholic fatty liver disease / insulin resistance / metabolic syndrome / nonalcoholic steatohepatitis / obesity
  •  go-up   go-down


46. Wang C, Xu YQ: Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative? Gastroenterology Res; 2008 Dec;1(1):2-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Diphenyl dimethyl bicarboxylate (DDB) has been used in some countries as hepatoprotectant adjuvant in the treatment of liver diseases, such as chronic viral hepatitis, chemical or drug induced hepatic damage.
  • Its early confirmed efficacy is to normalize elevated blood alanine aminotransferase (ALT) from different etiologies, however, it can rarely affect the rest hepatic enzymes.
  • Hence, for a long time, it has been only used as adjuvant of liver disease therapy.
  • It is still controversial that whether DDB can be beneficial to liver histology.
  • The normalization of ALT in hepatitis does not indicate therapeutic efficacy if without substantial liver histology improvement.
  • In recent years, more studies showed that DDB might have new therapeutical potentials in liver diseases, it may have the effect of anti-viral, anti-malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994699.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; adjuvant / dimethyl diphenyl bicarboxylate / liver disease / schisandra chinensis / schisandrin B / viral hepatitis
  •  go-up   go-down


47. Karimdjee BS Sr, Cambien MB, Richard MP, Bereder J Sr, Scoazec MJ, Birnbaum MD, Mounier MN, Schmid MH, Schmid MA: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. J Clin Oncol; 2009 May 20;27(15_suppl):e14619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14619 Background: Liver and lung metastases are the predominant cause of colorectal cancer (CRC) related mortality.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate hematopoetic cell movement are implicated in the metastatic process of malignant tumors, including that of CRC cells to lymph nodes.
  • To date, however, the contribution of CXCR3 to liver and lung metastasis in CRC has not been addressed.
  • METHODS: To determine whether CXCR3 receptors regulate malignancy-related properties of CRC cells, we have used CXCR3-expressing CRC cell lines of human (HT29 cells) and murine (C26 cells) origins that enable the development of liver and lung metastases when injected into immunodeficient and immunocompetent mice, respectively, and assessed the effect of CXCR3 blockade using AMG487, a small molecular weight antagonist.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited metastasis of human and mouse CRC cells to the lung without affecting that to the liver.
  • Also, we measured increased levels of CXCR3 and ligands expression within lung nodules compared to liver tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Alexandrova K, Griesel C, Barthold M, Heuft HG, Ott M, Winkler M, Schrem H, Manns MP, Bredehornsp T, Net M, Vidal MMI, Kafert-Kasting S, Arseniev L: Large-Scale Isolation of Human Hepatocytes for Therapeutic Application. Cell Transplant; 2005 Nov;14(10):845-853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last decade, hepatocyte transplantation has been suggested as a safe and potentially effective clinical option for the treatment of acute or decompensating chronic liver failure as well as for hereditary liver disease.
  • Currently, one of the major limiting factors for clinical application is the insufficient access to suitable liver cell preparations.
  • The mean specific yield was 3.6 × 106 total and 2.6 × 106 viable cells per gram liver tissue, respectively.
  • Specific cell yields from three infantile donor livers were considerably higher.
  • In summary, a standardized and cGMP conform method of hepatocyte isolation from nontransplantable liver organs was established, which reproducibly yields large amounts of hepatocytes suitable for therapeutic application.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28849979.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cell transplantation / GMP / Hepatocyte isolation / Steatosis
  •  go-up   go-down


49. Havelková M, Randák T, Žlábek V, Krijt J, Kroupová H, Pulkrabová J, Svobodová Z: Biochemical Markers for Assessing Aquatic Contamination. Sensors (Basel); 2007 Nov 02;7(11):2599-2611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The highest concentration of cytochrome P450 in fish liver was in the Vltava (0.241 nmol mg-1 protein), and the lowest was in the Orlice (0.120 nmol mg-1 protein).
  • The highest EROD activity in fish liver was in the Vltava (576.4 pmol min-1 mg-1 protein), and the lowest was in the Orlice (63.05 pmol min-1 mg-1 protein).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Toxicol Environ Health A. 1998 Mar 27;53(6):455-77 [9537282.001]
  • [Cites] Environ Pollut. 2005 Jul;136(2):231-42 [15840531.001]
  • [Cites] Chemosphere. 1997 May;34(9-10):2183-92 [9159913.001]
  • [Cites] Environ Toxicol Chem. 2001 Jan;20(1):149-59 [11351403.001]
  • [Cites] Drug Metab Dispos. 1997 May;25(5):564-72 [9152595.001]
  • [Cites] Ecotoxicol Environ Saf. 1994 Jun;28(1):35-42 [7523066.001]
  • [Cites] Environ Toxicol Chem. 2002 Sep;21(9):1864-75 [12206426.001]
  • [Cites] J Food Prot. 2007 Mar;70(3):706-15 [17388063.001]
  • [Cites] Gen Comp Endocrinol. 2003 Jun 15;132(2):223-30 [12812769.001]
  • [Cites] Sci Total Environ. 2006 Aug 31;367(2-3):715-31 [16740295.001]
  • [Cites] Comp Biochem Physiol C. 1987;86(2):233-45 [2882912.001]
  • [Cites] Chemosphere. 2007 Jan;66(3):542-52 [16860843.001]
  • [Cites] Ecotoxicol Environ Saf. 2002 Feb;51(2):145-53 [11886188.001]
  • [Cites] Chemosphere. 1998 Oct-Nov;37(9-12):2459-71 [9828349.001]
  • [Cites] Environ Toxicol Pharmacol. 2003 Feb;13(2):57-149 [21782649.001]
  • [Cites] Environ Sci Technol. 1994 Dec 1;28(13):2242-8 [22176041.001]
  • [Cites] Ecotoxicol Environ Saf. 1995 Jun;31(1):49-56 [7544264.001]
  • [Cites] Sci Total Environ. 2007 May 15;377(2-3):296-307 [17395248.001]
  • [Cites] Chemosphere. 2006 May;63(8):1342-52 [16289695.001]
  • [Cites] Environ Pollut. 2003;124(3):497-507 [12758029.001]
  • [Cites] Chemosphere. 2001 Apr;43(2):167-82 [11297396.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):157-75 [15325147.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Environ Monit Assess. 2007 Apr;127(1-3):47-54 [16957855.001]
  • [Cites] Environ Health Perspect. 1996 Aug;104 Suppl 4:741-803 [8880001.001]
  • [Cites] Bull Environ Contam Toxicol. 2006 Feb;76(2):233-41 [16468001.001]
  • [Cites] Environ Toxicol Chem. 2005 Aug;24(8):1968-78 [16152969.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 1;221(2):158-67 [17475301.001]
  • (PMID = 28903248.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; EROD / Leuciscus cephalus L. / River Elbe / cytochrome P450 / persistent organic pollutants
  •  go-up   go-down


50. Yang R, Tan X, Thomas AM, Shen J, Qureshi N, Morrison DC, Van Way CW 3rd: Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock. JPEN J Parenter Enteral Nutr; 2006;30(4):297-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock.
  • The hypothesis of the present study is that treatment with crocetin at the beginning of resuscitation suppresses subsequent expression of messenger ribonucleic acid (mRNA) for tumor necrosis factor (TNF-α), interleukin-1 (IL-1β) and inducible nitric oxide synthase (iNOS).
  • Liver samples were collected for reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA (TNF-α, IL-1β, iNOS, and β-actin).
  • RESULTS: Liver mRNA expression for TNF-α, IL-1β, and iNOS was found in more animals in the shock and shock-plus-resuscitation groups than in the sham control group.
  • CONCLUSIONS: Crocetin modified the hepatic mRNA expression of cytokines and iNOS in a shock model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059007.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Bensalem A, Bouzid K: Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of metastases were liver in 14 ( 77.7%), lung in 5 (27.7%) and bone in 9 (50%).
  • The main toxicities were as follows: neutropenia grade 3 in 3 patients (16.6 %), anemia grade 2-3 in 2 patients (11.1%), fatigue in 2 patients (11.1%), hand-foot syndrome in 7 patients (38.9%), vomiting-nausea in 4 patients (22.2%), diarrhea in 2 patients (11.1%), liver toxicity in 3 patients (16.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964240.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Artinyan A, Castillo E, Foster B, Wagman L: Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases.
  • : e15009 Background: The treatment of hepatic colorectal cancer metastases is increasingly multi-modal.
  • MATERIALS AND METHODS: 149 patients who had undergone liver resection or biopsy for hepatic colorectal cancer metastases were identified from an institutional database.
  • Preoperative non-contrast CT scans were reviewed for evidence of steatosis as determined by the radiographic liver/spleen (L/S) ratio.
  • In patients undergoing liver resection, there was no difference in total ICU stay, blood loss, total surgery time or total length of stay between the steatohepatitis and non-steatohepatitis groups.
  • CONCLUSIONS: Although steatohepatitis remains a potential complication of systemic chemotherapy in surgical patients with hepatic colorectal metastases, the risk and impact of chemotherapy associated steatohepatitis have not been significant in our patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964364.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Yopp AC, Shia J, Allen PJ, DeMatteo RP, Jarnagin WR, Fong Y, Blumgart L, D'Angelica MI: Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):11081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases.
  • : 11081 Background: Expression of the chemokine receptors CXCR4 and CCR7 has been associated with metastases and poor prognosis in primary tumors but their relevance in colorectal liver metastases (CLM) is unclear.
  • This study examines the relationship between tumor chemokine receptor expression, pattern of recurrence and outcome after resection of hepatic metastases.
  • METHODS: Eighty patients with metastases from colon or rectal primary tumors who underwent a R<sub>0</sub> partial hepatectomy from February 2002 to April 2004 were studied prospectively.
  • Immunohistochemical staining was performed on the formalin-fixed, paraffin-embedded tissues of hepatic metastases using antibodies specific for CXCR4, CXCL12 and CCR7.
  • Positive expression of CXCR4, CXCL12 and CCR7 was seen in 49 (61%), 23 (29%) and 48 (60%) of tumor specimens, respectively.
  • CCR7 and CXCL12 expression, hepatic artery infusion pump chemotherapy, systemic chemotherapy and site of primary disease did not influence DSS or RFS.
  • Fifty-three (68%) of the patients recurred; 11 with liver only recurrences, 25 with lung only recurrences and 18 with multiple sites of recurrences.
  • CONCLUSIONS: CXCR4 expression in colorectal hepatic metastases adds prognostic information with regards to DSS, RFS and patterns of recurrence and may play role in clinical decision making regarding chemotherapy and surgical interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Vogl TJ, Naguib N, Zangos S, Eichler K, Gruber T: Repeated transarterial chemoperfusion and -embolization (TACE) in primary hepatic cholangiocarcinoma (CCC): Local tumor control and survival rate. J Clin Oncol; 2009 May 20;27(15_suppl):e15595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated transarterial chemoperfusion and -embolization (TACE) in primary hepatic cholangiocarcinoma (CCC): Local tumor control and survival rate.
  • : e15595 Background: To evaluate local tumor control and survival data in the palliative and symptomatic treatment of hepatic cholangiocarcinoma (CCC) using repeated transarterial chemoperfusion and -embolization (TACE) with two different chemotherapy protocols.
  • 22 patients had multiple tumors, 6 showed 1 lesion, 5 had 2 lesions and 8 presented 3 to 4 lesions.
  • Tumor response was evaluated by magnetic resonance imaging (MRI) in 3-month intervals.
  • RESULTS: Evaluation of local tumor control according to the RECIST criteria was as follows: partial response 9.8%, stable disease 43.6%, and progressive disease 46.6%.
  • The mean survival time from the date of diagnosis of liver involvement was 34.1 months (according to Kaplan-Meier), after first TACE treatment 16.7 months.
  • CONCLUSIONS: Our data indicated that repeated TACE using the protocols is well tolerated and yields respectable results in patients with unresectable liver lesions from CCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962884.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Lencioni R, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Lammer J: A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. J Clin Oncol; 2009 May 20;27(15_suppl):4523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a drug-eluting bead (DEB) has been developed to enhance drug delivery to the tumor and reduce its systemic availability.
  • METHODS: Two hundred and twelve patients (185 males and 27 females; mean age, 67 years) with Child-Pugh A or B liver cirrhosis and large and/or multinodular, unresectable HCC were randomized to receive DEB-TACE (DC Bead; Biocompatibles, UK) uploaded with doxorubicin or conventional TACE with doxorubicin, lipiodol, and gelatin sponge particles.
  • Tumor response at 6 months was the primary study endpoint.
  • An independent, blinded review of magnetic resonance imaging studies was conducted to assess tumor response according to amended RECIST criteria.
  • There was a marked reduction in serious liver toxicity in patients treated with DEB-TACE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Vigo SA, Sansano M, Marmissolle F, Mainella A, Lujan L, Price P, Antonelli M, Mohamed F, Giacomi N: Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.
  • It is believed that tumor is more aggressive in biologic nature in this group of pts.
  • OBJECTIVE: to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC.
  • METHODS: We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007.
  • RESULTS: Her2/neu overexpression showed up in 8 tumors (17.7%) and all of them were confirmed by FISH.
  • Stage at diagnosis was I 2 pts and II 6 pts.
  • 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis.
  • Postoperative radiotherapy was given to 6pts while all pts with Her2/neu positive tumors received chemotherapy with anthracyclines, taxanes and trastuzumab.
  • Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases.
  • In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm.
  • Progressive disease with distant metastases in bone, lung and liver was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Van Der Windt DJ, Echeverri GJ, Ijzermans JNM, Cooper DKC: The Choice of Anatomical Site for Islet Transplantation. Cell Transplant; 2008 Sep;17(9):1005-1014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, other sites, such as the omentum, offer drainage of produced insulin into the portal vein for direct utilization in the liver.
  • Eventually, the liver will most likely be replaced by a site that allows long-term survival of islets from a single donor to reverse type 1 diabetes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863751.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immune privilege / Intraportal / Islet transplantation / Omental pouch / Subcutaneous / Xenotransplantation
  •  go-up   go-down


58. Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, Falandry C, Lebrun D, Pujade-Lauraine E, GINECO-Group: Clinical presentation and sensitivity to platinum-based chemotherapy (CT) of mucinous advanced epithelial ovarian carcinoma (M-AEOC): The GINECO-Group experience. J Clin Oncol; 2009 May 20;27(15_suppl):5572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extra-peritoneal mets (stage IV) were more frequent in M- than in S-AEOC pts (30% versus 15%, p = 0.004), specially liver mets (44% of stage IV pts versus 23%, p = 0.06).
  • CONCLUSIONS: Compared to S-AEOC, M-AEOC is characterized by more limited peritoneal carcinomatosis but more frequent liver mets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962610.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Demetris AJ, Fontes P, Lunz JG 3rd, Specht S, Murase N, Marcos A: Wound Healing in the Biliary Tree of Liver Allografts. Cell Transplant; 2006 Jan;15(1_suppl):57-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wound Healing in the Biliary Tree of Liver Allografts.
  • An increasing need for liver transplantation requires evaluation and triage of organs harvested from "extended criteria" donors.
  • These organs carry a statistical risk of dysfunction early after transplantation, but in the majority of recipients, hepatic parenchymal function recovers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863771.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Biliary strictures / Liver transplantation / Wound healing
  •  go-up   go-down


60. Nwokediuko SC, Ibegbulam O: Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. Gastroenterology Res; 2009 Dec;2(6):344-349

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease.
  • Quantitative abnormalities of platelets are known to occur in chronic liver disease.
  • The study was carried out to determine the abnormalities of platelet count in various forms of Hepatitis B virus-related liver disease.
  • METHODS: Platelet count was carried out on consecutive chronic liver disease patients seen at the gastroenterology unit of the University of Nigeria Teaching Hospital Ituku/Ozalla who tested positive for Hepatitis B surface antigen (HBsAg) from January 2007 to June 2009.
  • RESULTS: There were 142 patients with various forms of HBV-related liver disease (asymptomatic infection 29.6%, chronic hepatitis 8.4%, cirrhosis 27.5%, and hepatocellular carcinoma 34.5%).
  • There was no statistically significant difference between the mean platelet count in the patients with Hepatitis B virus (HBV) related liver disease as a whole and control subjects (p = 0.4655).
  • CONCLUSIONS: Abnormalities of platelet count occur in HBV-related liver disease.
  • Patients with liver cirrhosis tend to have lower platelet count while patients with HCC tend to have higher counts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990204.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Hepatitis B virus / Liver disease / Paraneoplastic syndrome / Platelet
  •  go-up   go-down


61. Cunningham SC, Dane AP, Spinoulas A, Alexander IE: Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors. Mol Ther; 2008 Jun;16(6):1081-1088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors.
  • : Recombinant adeno-associated viral (rAAV) vectors have shown promise for use in liver-targeted gene delivery, but their effects have not been extensively investigated in the immature liver.
  • Understanding the impact of liver growth on the efficacy of transduction is essential, because many monogenic liver diseases that are amenable to gene therapy will require treatment early in life.
  • Here we show that rAAV2/8 transduces the neonatal mouse liver with high efficiency.
  • With just one doubling in liver weight, however, there is a rapid reduction in vector genome numbers, irrespective of form, and the loss of episomal vector is almost complete by 2 weeks.
  • We also found that intraperitoneal (IP) delivery of rAAV2/8 was highly effective at all ages, and that promoter selection is the critical determinant of the intensity and pattern of transgene expression across the hepatic lobule.
  • We conclude that successful use of rAAV to treat liver disease in early childhood will require optimally efficient vector constructs and probable re-administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178471.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Rojas Llimpe F, Di Fabio F, Ercolani G, Giampalma E, Serra C, Castellucci P, Pini S, Mutri V, Golfieri R, Pinto C, Martoni A: Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study). J Clin Oncol; 2009 May 20;27(15_suppl):e15010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study).
  • : e15010 Background: The aim of the study was to define the specific diagnostic accuracy of different imaging techniques in patients (pts) with resectable colorectal cancer liver metastasis (CLMs).
  • METHODS: Consecutive pts with, potentially resectable CLMs afferent to the Multidisciplinary Liver Team of Bologna Sant'Orsola Malpighi Hospital performed, in the 3 weeks prior to liver surgery, computed tomography scan (CT), magnetic resonance diffusion-weighted (MR-DW), and liver contrast-enhanced ultrasonography (CEUS1).
  • Liver contrast-enhanced ultrasonography was also performed intra-operatively (CEUS2).
  • RESULTS: From December 2007 to December 2008, twenty-nine out of 50 pts enrolled in the PROMETEO study underwent liver resection.
  • The pt characteristics were: 18 (62%) males, 11 (38%) females; 18 (62%) synchronous metastasis, 11 (38%) metachronous metastasis; 15 (51.7%) neoadjuvant chemotherapy; 7 (24.1%) previous liver surgery; 3 (10.3%) previous loco-regional treatment.
  • Ninety-three liver lesions were resected; the median number lesions per patient was 2 (range 1- 10).
  • CONCLUSIONS: These results show that CT, CEUS1 and MR-DW have a good accuracy in the detection of liver metastasis in patients who are candidates for resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Li H, Lu Y, Witek RP, Chang LJ, Campbell-Thompson M, Jorgensen M, Petersen B, Song S: Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin. Mol Ther; 2010 Aug;18(8):1553-1558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin.
  • We have previously shown that liver progenitor (oval) cells can be used as a platform for liver gene delivery of human α1-antitrypsin (hAAT).
  • In the present study, we tested the feasibility of bone marrow (BM) cell-based liver gene delivery of hAAT.
  • Transplantation studies showed that transplanted BM cells homed into liver, differentiated into hepatocytes and expressed hAAT in the liver.
  • These results demonstrated that rAAV vector-mediated BM cell-based liver gene therapy is feasible for the treatment of AAT deficiency and implies a novel therapy for the treatment of liver diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178512.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Azoulay D, Bismuth H, Castaing D, Adam R: Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases.
  • : 4097 Background: Regenerative nodular hyperplasia (RNH) represents the worst evolutive stage of vascular lesions induced by prolonged chemotherapy on the liver.
  • Its incidence and impact on the outcome of resection for colorectal liver metastases (CLM) are however unknown.
  • Detailed histopathologic analysis of the nontumoral liver was performed at first and repeat hepatectomies according to a standard format.
  • The presence of RNH was associated with increased postoperative hepatic morbidity (23% vs 11%) (P=0.05).
  • CONCLUSIONS: Patients with CLM that receive prolonged courses of preoperative oxaliplatin have an increased risk of RNH and associated postoperative hepatic morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Vaklavas C, Tsimberidou AM, Moulder S, Ng C, Naing A, Daring S, Bedikian A, Uehara C, Kurzrock R: A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement. J Clin Oncol; 2009 May 20;27(15_suppl):e13512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement.
  • : e13512 Background: Patients with liver metastases treated on phase I clinical trials have a median survival of 7.5 months (range, 6.0-9.5).
  • We conducted a phase I study of hepatic arterial infusion (HAI) and intravenous (IV) chemotherapy in patients with advanced cancer and dominant liver involvement.
  • Treatment resulted in a partial response (PR)(n=4) or stable disease (SD)(n=6) by RECIST in 10 (48%) patients and lasted for ≥4 months (tumor reduction by 5% to 44%).
  • Four (19%) patients achieved a PR (tumor reduction by 38%, 42%, 44% and 51%, for 4, 4, 6, and 4 months, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Valori R: Non-alcoholic fatty liver disease: a non-problem or public health catastrophe? Frontline Gastroenterol; 2010 Oct;1(3):147-148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-alcoholic fatty liver disease: a non-problem or public health catastrophe?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2010 May 8;375(9726):1624-33 [20430429.001]
  • (PMID = 28839567.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM: Corrigendum to "Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates". Mol Ther; 2006 Jul;14(1):150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corrigendum to "Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28192691.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] United States
  •  go-up   go-down


68. Deurholt T, Ten Bloemendaal L, Chhatta AA, Van Wijk ACWA, Weijer K, Seppen J, Elferink RPJO, Chamuleau RAFM, Hoekstra R: In Vitro Functionality of Human Fetal Liver Cells and Clonal Derivatives under Proliferative Conditions. Cell Transplant; 2006 Sep/Oct;15(8-9):811-822

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In Vitro Functionality of Human Fetal Liver Cells and Clonal Derivatives under Proliferative Conditions.
  • In contrast, human fetal liver cells (HFLC) can be easily expanded in vitro.
  • In this study we evaluated the hepatic function of HFLCs under proliferative conditions, to determine whether HFLCs can replace mature hepatocytes for in vitro applications.
  • HFLCs were isolated from fetal livers of 16 weeks gestation.
  • Hepatic functions of HFLCs were determined in primary culture and after expansion in vitro.
  • Clonal derivatives were selected and tested for hepatic functionality.
  • No differences were observed between primary HFLCs and mature human hepatocytes in albumin production and mRNA levels of various liver-specific genes.
  • Expanding HFLCs decreased hepatic functions and increased cell stretching.
  • Although their hepatic functions were higher than in passaged HFLCs, functionality was at least 20 times lower compared to mature human hepatocytes.
  • HFLCs cannot replace mature human hepatocytes in in vitro applications requiring extensive in vitro expansion, because this is associated with decreased hepatic functionality.
  • In addition, defining conditions that support hepatic differentiation is necessary to obtain HFLC cultures suitable for in vitro hepatic applications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876098.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Fetal / Hepatocyte / In vitro / Liver function / Proliferation
  •  go-up   go-down


69. Saunders J, Brian A, Wright M, Stroud M: Malnutrition and nutrition support in patients with liver disease. Frontline Gastroenterol; 2010 Jul;1(2):105-111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malnutrition and nutrition support in patients with liver disease.
  • Liver disease, especially alcohol related, is increasingly common and is often accompanied by malnutrition as a result of reduced intake, absorption, processing and storage of nutrients.
  • Malnutrition in all forms of liver disease is associated with higher rates of mortality and morbidity but it is often under recognised and under treated despite the fact that appropriate treatment can improve outcomes.
  • In this review, the causes, consequences and assessment of nutritional status in patients with liver disease are examined, and an approach to best treatment is proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JPEN J Parenter Enteral Nutr. 1993 Mar-Apr;17(2):119-24 [8455312.001]
  • [Cites] Gastroenterology. 1991 Mar;100(3):738-44 [1993495.001]
  • [Cites] Hepatology. 1983 Jul-Aug;3(4):475-80 [6345330.001]
  • [Cites] Clin Nutr. 2006 Apr;25(2):285-94 [16707194.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):536-41 [9073135.001]
  • [Cites] Clin Nutr. 2009 Aug;28(4):436-44 [19520466.001]
  • [Cites] Nutrition. 2005 Feb;21(2):113-7 [15723736.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13 [16206505.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):807-11 [12190094.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):200-5 [1727754.001]
  • [Cites] Nutrition. 2001 Jun;17(6):445-50 [11399401.001]
  • [Cites] Am J Clin Nutr. 1999 Jun;69(6):1194-201 [10357739.001]
  • [Cites] Transpl Int. 1997;10(5):369-74 [9287402.001]
  • [Cites] Clin Nutr. 1997 Apr;16(2):43-55 [16844569.001]
  • [Cites] Eur J Clin Nutr. 1989 Sep;43(9):615-21 [2691239.001]
  • [Cites] BMJ. 1989 Nov 11;299(6709):1202-3 [2513050.001]
  • [Cites] Transplantation. 2000 Apr 15;69(7):1364-9 [10798755.001]
  • [Cites] Hepatology. 2009 Jun;49(6):2087-107 [19475696.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1208-15 [11093726.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e43-8 [17683494.001]
  • [Cites] Hepatology. 1996 May;23(5):1041-6 [8621131.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):228-33 [14739092.001]
  • [Cites] J Hepatol. 1994 Dec;21(6):940-6 [7699257.001]
  • [Cites] Proc Nutr Soc. 2007 Aug;66(3):378-83 [17637090.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Apr;23(4):606-10 [18005013.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):476-82 [16799890.001]
  • [Cites] Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41 [4044297.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4837-43 [14568963.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1257-66 [17490961.001]
  • [Cites] J Nutr. 1994 Jun;124(6):906-10 [7515956.001]
  • [Cites] Clin Nutr. 1989 Dec;8(6):329-36 [16837309.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD001939 [12804416.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1792-801 [12806613.001]
  • [Cites] Hepatology. 2006 Oct;44(4):823-35 [17006918.001]
  • [Cites] Liver Transpl. 2000 Sep;6(5):575-81 [10980056.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):38-43 [15246205.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):837-40 [7916398.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):715-20 [2105256.001]
  • [Cites] Br J Nutr. 1995 Oct;74(4):557-67 [7577893.001]
  • [Cites] J Hepatol. 1994 Sep;21(3):317-25 [7836699.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1194-201 [17919230.001]
  • [Cites] Liver. 1985 Oct;5(5):282-9 [4079669.001]
  • (PMID = 28839557.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


70. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Todo S: Establishment of Immortalized Human Hepatocytes by Introduction of HPV16 E6/E7 and hTERT as Cell Sources for Liver Cell-Based Therapy. Cell Transplant; 2008 Sep;17(9):1083-1094
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of Immortalized Human Hepatocytes by Introduction of HPV16 E6/E7 and hTERT as Cell Sources for Liver Cell-Based Therapy.
  • For future cell-based therapies for liver diseases, the shortage of cell sources must be resolved.
  • Albumin synthesis and expression of liver-enriched genes were confirmed, but gradually decreased as passages progressed.
  • Subcutaneous injection of these cells into severe combined immunodeficiency (SCID) mice did not induce tumor development.
  • Intrasplenic transplantation of dedifferentiated HHE6E7T-1 cells over 200 PDs significantly improved the survival of acetaminophen-induced acute liver failure SCID mice.
  • However, the results of intrasplenic transplantation to SCID mice with acetaminophen-induced acute liver failure showed the possibility of HHE6E7T-1 serving as a cell source for hepatocyte transplantation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863749.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acetaminophen-induced acute liver failure / Chromosomal instability / Dedifferentiation / Hepatocyte transplantation / Tumorigenicity
  •  go-up   go-down


71. Quesson B, Merle M, Köhler MO, Mougenot C, Roujol S, de Senneville BD, Moonen CT: A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver. Med Phys; 2010 Jun;37(6Part1):2533-2540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver.
  • PURPOSE: High intensity focused ultrasound (HIFU) is a promising method for the noninvasive treatment of liver tumors.
  • The method was validatedex vivo and in vivo in pig liver during breathing under multislice real-time MR thermometry, using the proton resonance frequency shift method.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512934.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acoustic transducers / Biothermics and thermal processes in biology / HIFU / Liver / MR thermometry / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Medical magnetic resonance imaging / Segmentation / Tissue ablation / Tissues / Transducers / Ultrasonic transducers / Ultrasonography / biomedical MRI / biothermics / bone / image segmentation / liver / medical image processing / rib / skin / tumours / ultrasonic therapy
  •  go-up   go-down


72. Adam R, Wicherts DA, de Haas RJ, Lévi F, Paule B, Azoulay D, Castaing D: Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):4093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab.
  • : 4093 Background: The influence of bevacizumab on postoperative morbidity in patients with colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated.
  • However, in spite of a potential inhibition of liver regeneration, its impact on postoperative liver function recovery remains unknown.
  • Postoperative evolution of liver function variables was compared with that of 70 bevacizumab-naïve patients.
  • Baseline liver function tests as well as postoperative liver function recovery were similar between patients treated with or without bevacizumab (Table).
  • CONCLUSIONS: Preoperative bevacizumab treatment has no impact on short-term liver function recovery after hepatic resection for CLM and has no deleterious effect on the incidence of postoperative morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Benedict SH, Bova FJ, Clark B, Goetsch SJ, Hinson WH, Leavitt DD, Schlesinger DJ, Yenice KM: The role of medical physicists in developing stereotactic radiosurgery. Med Phys; 2008 Sep;35(9):4262-4277

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A major theme of the article is the expanding role of the medical physicist from that of advisor to the neurosurgeon to the current role as a primary driver of new technology that has already led to an adaptation of cranial SRS to other sites in the body, including, spine, liver, and lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 The Authors. Published by American Association of Physicists in Medicine and John Wiley & Sons Ltd.
  • (PMID = 28525045.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Collimators / Dosimetry / Dosimetry/exposure assessment / Linear accelerators / Medical imaging / Medical physicists / Physicists / Protons / Radiation therapy / Radiation treatment / Radiosurgery / Stereotactic radiosurgery / dosimetry / liver / lung / neurophysiology / radiation therapy / stereotactic body radiotherapy / stereotactic radiosurgery / stereotactic radiotherapy / surgery
  •  go-up   go-down


74. Osako T, Nishimura R, Okumura Y, Hayashi M: Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population. J Clin Oncol; 2009 May 20;27(15_suppl):e11548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Aprile G, Miscoria M, Baldin P, Casetta A, Pandolfi M, Di Loreto C, Pizzolitto S, Pizzolitto S, Foltran L, Fasola G, Puglisi F: Chemotherapy-induced thymidine phosphorylase modulation in colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of biopsied metastases were liver (n=41), lung (n=10), and peritoneum (n=6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U: Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). J Clin Oncol; 2009 May 20;27(15_suppl):5108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5108 Background: S, T (temsirolimus) and E (everolimus) are primarily metabolized in the liver, while the metabolism of B is unclear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Tumor down-staging was observed in 10pts (66.6%), including 5pts with complete pathological response (33.3%).
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Toumpanakis C, Quigley A, Srirajaskanthan R, Marelli L, Singhrao T, Meyer T, Buscombe J, Caplin ME: 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors.
  • : 4594 Background: The expression of somatostatin receptors (SSTR) on Neuroendocrine Tumors (NETs) has led not only to tumour visualization utilizing SSTR scintigraphy, but also to the development of receptor-targeted radionuclide therapy.
  • Isotopes such as 111-Indium, 90-Yttrium and 177-Lutetium are linked to somatostatin analogues and then internalized by tumour cells.
  • In all patients, the tumours had shown good uptake either in the OctreoScan or in the Ga-68 octreotate PET scan.
  • 29/89 patients included a cycle of intra-arterial therapy with mean dose/cycle 2090 MBq for large volume liver disease.
  • RESULTS: In all patients the post treatment scintigraphy demonstrated good uptake and localization by the tumors.
  • 31/89 (35%) had continued tumor progression.
  • CONCLUSIONS: 90Y-DOTA-octreotate is a well-tolerated and safe treatment for patients with progressive neuroendocrine tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963114.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT Jr, Fox FE, Voss S, Adamson PC, Blaney SM: A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol; 2009 May 20;27(15_suppl):10013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.
  • : 10013 Background: IMC-A12, a fully human IgG1 monoclonal antibody to the Insulin-Like Growth Factor-I Receptor (IGF-IR), is active preclinically in a variety of pediatric solid tumors.
  • We performed a phase I trial to determine the toxicities, maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics (PD) of IMC-A12 in children with refractory solid tumors.
  • Grade 2 or higher non-DLTs possibly attributable to IMC-A12 observed in the first course include anemia (n=4), leukopenia (n=1), lymphopenia (n=2), neutropenia (n=2), opportunistic infection (n=1), ↑liver transaminases (n=2), and hyperglycemia (n=1).
  • CONCLUSIONS: In order to exceed target trough concentrations associated with optimal anti-tumor activity in pre-clinical models, 9 mg/kg IV weekly is the recommended Phase II IMC-A12 dose in children.
  • A phase II protocol for children with refractory solid tumors will be performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962525.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. De Castro J, Cejas P, Belda-Iniesta C, Ramirez-Merino N, Barriuso J, Hernandez-Agudo E, Feliu J, Moreno-Garcia V, Martinez-Marin V, Gonzalez-Baron M: Is hepcidin involved in anemia of advanced non-small cell lung carcinoma (NSCLC) patients treated with platin-based chemotherapy? An exploratory study. J Clin Oncol; 2009 May 20;27(15_suppl):e19086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepcidin, a liver-produced peptide, acts to cause a block on cellular iron export by internalisation and degradation of ferroportin.This results in iron sequestration and interrupts iron delivery to erythroid precursor cells thus causing anemia.
  • Only 10% were anemic at the diagnosis but 70% developped anemia during the treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Harrop R, Shingler WH, Goonewardena M, de Belin J, Kelleher M, Drury N, Treasure P, Naylor S: Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):3058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3058 Background: The attenuated vaccinia virus MVA has been engineered to deliver the tumor antigen 5T4 (MVA-5T4; TroVax).
  • 5T4 is a surface glycoprotein expressed by most solid tumors.
  • METHODS: Patients with histologically proven CRC were recruited to 4 independent trials in which 3 to 6 vaccinations of MVA-5T4 were scheduled to be administered either as a monotherapy, as adjuvant/neoadjuvant to surgery for respectable liver metastases or alongside treatment with FOLFIRI or FOLFOX.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hertz P, Seruga B, Le LW, Tannock IF: Global drug development in cancer: A cross-sectional study of clinical trial registries. J Clin Oncol; 2009 May 20;27(15_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer sites that are major killers globally, and especially in the LDW (e.g., stomach, liver, and esophageal cancer) should receive priority for clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Jansen M, Vernaz-Gris M, DesJardins C, Wong N, Campone M, Cortes J, Wanders J, Shuster D, Fuseau E: Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):2524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appreciable interpatient PK variability exists, a minor fraction of which was explained by measures of liver and renal function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Perez-Staub N, Chibaudel B, Paye F, Taieb J, Gayet B, Bourges O, André T, Tournigand C, Louvet C, de Gramont A: Survival after surgery in patients with initially resectable metastasis receiving adjuvant/neoadjuvant FOLFOX therapy and in patients who had surgery after FOLFOX therapy. J Clin Oncol; 2009 May 20;27(15_suppl):4118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients' baseline characteristics were (MIROX/OPTIMOX %): median age 56/62 yrs, PS 0 50/73, metachronous metastasis 41/21, ≥ 2 met sites 11/18, liver met 78/88, lung met 11/19, other met 17/10, two-stage surgery 9/10, second surgery after relapse 39/22, R0 resection 91/ 85.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961218.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, Roullet B, Hasbini A, Savary J, Cellier P: Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):4104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 172 pts underwent surgery (97.2%), 5 pts were not resected (4 liver and 1 lung metastases plus 1 CVA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Besse-Hammer T, Villanueva C, Campone M, Machiels J, Awada A, Magherini E, Dubin F, Semiond D, Pivot XB: A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):1053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for the first 25 pts, are available so far: median age 52 [34-74], ECOG-PS 0/1: 15/10, in first or second line chemotherapy, median of 3 (1-7) organs involved (mainly: bone, liver, lymph nodes).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961150.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X: Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ixa/bev has greater preclinical activity than pac/bev in human tumor models.
  • Baseline characteristics were balanced between arms except for liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961032.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Neumann UP, Fotopoulou C, Neuhaus P, Sehouli J: Clinical outcome of resection of liver metastasis in patients with ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of resection of liver metastasis in patients with ovarian cancer.
  • : e16545 Background: Hepatic resection has become the standard treatment for resectable colorectal liver metastases.
  • However, in patients with ovarian cancer resectable liver metastases are rare and the issue is discussed controversially due to the lack of relevant published data.
  • The aim of this retrospective study was to evaluate the efficacy of hepatic resections in patients with ovarian cancer.
  • METHODS: Between 1991 and 2006 a total of 73 women with liver metastases underwent surgery for ovarian cancer.
  • In 40 patients a liver resection was performed.
  • RESULTS: Residual tumor after surgery was by far the strongest predictor for outcome.
  • Median survival in patients with no residual tumor was 65 months, < 0.5 cm 29 months, 1cm 6 months.
  • This data clearly show that macroscopically complete surgical cytoreductive therapy improves long-term survival in patients with ovarian cancer and liver metastases.
  • Therefore, liver resection should be always discussed if complete resection is achievable and should be part of the multimodal strategy in advanced ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Gyergyay F, Nagyványi K, Bodrogi I: Decreased toxicity schedule of suitinib in renal cell cancer: 2 weeks on/1 week off. J Clin Oncol; 2009 May 20;27(15_suppl):e16113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 36 pts, median age 59.5 yrs (range 42-83), M/F (26:10), ECOG: 0 (21); 1 (9); 2 (6); prior nephrectomy (35),prior radiation therapy (28), prior cytokine therapy: IFNα (25), IL-2+IFNα (9) none (2); pts with 1 metastatic organ (24); 2 metastatic sites (7); ≥ 3 sites (5); Sites of metastases: Lung (27), Bone (11), Liver (3); MSCC risk factors: 0 (20), 1-2 (14); ≥3 (2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963329.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Ueno M, Ohkawa S, Sakamoto Y, Miyakawa K, Miyagi Y: The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissues were obtaind from liver; 12, pancreas; 19.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Okamoto I, Kaneda H, Satoh T, Okamoto W, Terashima M, Arao T, Nishio K, Nakagawa K, Konishi K, Kaiser R: Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):3572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor.
  • METHODS: BIBF 1120 (150-250 mg) was administered orally twice-daily (bid) to heavily pre-treated solid tumor (ST) patients to determine safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics (PK).
  • Dose-limiting toxicities (DLTs) of reversible Grade 3/4 elevated liver enzymes occurred in three of 12 patients at 200 mg bid and three of six patients at 250 mg bid; 200 mg bid was declared as the MTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Li H, Gu ZK, Li XS, Hou CM, Tang PH, Mao N: Functional and Phenotypic Alteration of Intrasplenic Lymphocytes Affected by Mesenchymal Stem Cells in a Murine Allosplenocyte Transfusion Model. Cell Transplant; 2007 Jan;16(1):85-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo eGFP tracing with polymerase chain reaction analysis revealed that grafted MSCs could migrate and settle into the lungs, spleen, liver, intestine, and skin shortly after administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880677.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immunomodulation / In vivo / Lymphocyte subsets / Mesenchymal stem cells / Murine model
  •  go-up   go-down


93. Jones GL, Juszczak MT, Hughes SJ, Kooner P, Powis SH, Press M: Time Course and Quantification of Pancreatic Islet Revasculariztion following Intraportal Transplantation. Cell Transplant; 2007 May;16(5):505-516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syngeneic islets were transplanted selectively into the two right posterior lobes of the liver of adult Lewis rats.
  • Sections of the livers were dual stained for insulin and Bandeiraea simplicifolia and analyzed for islet morphology, area, and vascular density from day 0 to day 14 posttransplant and compared to native islets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28866940.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Endothelium / Islet transplantation / Quantification / Vascular density
  •  go-up   go-down


94. Chaturvedi P, Machacha CNE: Efficacy of Raphanus sativus in the treatment of paracetamol-induced hepatotoxicity in albino rats. Br J Biomed Sci; 2007 Jan;64(3):105-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the efficacy of a methanol extract of Raphanus sativus root (RSME) is tested in albino rats that developed hepatic damage due to administration of paracetamol (100 mg/kg body weight) for 30 days.
  • RSME reduced lipid peroxidation induced by paracetamol and brought the levels of SGOT and SGPT to normal, indicating liver recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28705144.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Catalase / Glutathione / Lipid peroxidation / Raphanus sativus / Thiobarbituric acid reactive substance
  •  go-up   go-down


95. Pérez-López FR, Pérez-Roncero G, López-Baena MT: Vitamin D and adolescent health. Adolesc Health Med Ther; 2010;1:1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-dose calcifediol depots are an alternative for guaranteeing treatment adherence and in patients with liver disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2008 Nov;122(5):1142-52 [18977996.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4702-12 [10599739.001]
  • [Cites] J Am Diet Assoc. 2004 Jun;104(6):980-3 [15175600.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000369 [19197344.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Sep;94(9):3200-6 [19549742.001]
  • [Cites] Med Hypotheses. 2008;70(4):750-9 [17920208.001]
  • [Cites] Can J Public Health. 2005 Nov-Dec;96(6):443-9 [16350869.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e371-9 [19661053.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):537-53, vii [16085158.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):33-8 [16618499.001]
  • [Cites] Maturitas. 2008 Feb 20;59(2):101-13 [18289805.001]
  • [Cites] Am J Clin Nutr. 2002 Dec;76(6):1446-53 [12450915.001]
  • [Cites] Arch Dis Child. 2005 Apr;90(4):373-8 [15781927.001]
  • [Cites] Ann Nutr Metab. 2009;54(1):15-21 [19194104.001]
  • [Cites] J Nutr. 2005 Feb;135(2):279-82 [15671226.001]
  • [Cites] Arch Intern Med. 2009 Mar 23;169(6):626-32 [19307527.001]
  • [Cites] Metabolism. 2008 Feb;57(2):183-91 [18191047.001]
  • [Cites] Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-645S [7879731.001]
  • [Cites] Bone. 2003 Aug;33(2):242-7 [14499358.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jan;80(1):54-8 [9915372.001]
  • [Cites] Mol Genet Metab. 2009 Mar;96(3):113-20 [19147383.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1956-64 [15637289.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1060-5 [1400871.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):76-85 [17983444.001]
  • [Cites] Calcif Tissue Int. 1998 Nov;63(5):369-74 [9799819.001]
  • [Cites] Atherosclerosis. 2009 Jul;205(1):255-60 [19091317.001]
  • [Cites] Endocrinol Nutr. 2009 Apr;56(4):164-9 [19627732.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2832-8 [17179460.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2117-9 [19349538.001]
  • [Cites] Osteoporos Int. 2009 Jan;20(1):133-40 [18458986.001]
  • [Cites] Arch Dermatol. 1991 Apr;127(4):536-8 [1848745.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2693-701 [18445674.001]
  • [Cites] J Bone Miner Res. 1995 May;10(5):711-5 [7639106.001]
  • [Cites] J Bone Miner Res. 1998 Oct;13(10):1602-12 [9783549.001]
  • [Cites] Eur J Clin Nutr. 2005 Apr;59(4):533-41 [15714215.001]
  • [Cites] Environ Health Perspect. 2007 Aug;115(8):1132-9 [17687438.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):777-83 [9504937.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):1962-71 [11697792.001]
  • [Cites] Pediatrics. 2008 Aug;122(2):398-417 [18676559.001]
  • [Cites] J Neurol. 2009 Sep;256(9):1468-79 [19399382.001]
  • [Cites] Eur J Clin Nutr. 1999 Sep;53(9):746-51 [10509773.001]
  • [Cites] JAMA. 1992 Nov 4;268(17):2403-8 [1404797.001]
  • [Cites] Curr Med Chem. 2010;17(5):453-66 [20015037.001]
  • [Cites] Arch Pediatr Adolesc Med. 2005 Apr;159(4):335-41 [15809385.001]
  • [Cites] Arch Dis Child. 2008 Jun;93(6):512-7 [18339654.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2735S-8S [16251640.001]
  • [Cites] Bone. 1995 Dec;17(6):513-6 [8835303.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1545-56 [8889856.001]
  • [Cites] Calcif Tissue Int. 2007 Nov;81(5):352-63 [17989943.001]
  • [Cites] Maturitas. 2009 Mar 20;62(3):248-62 [19211206.001]
  • [Cites] Maturitas. 2007 Oct 20;58(2):117-37 [17604580.001]
  • [Cites] Aten Primaria. 2008 Aug;40(8):393-9 [18755099.001]
  • [Cites] Diabetologia. 2008 Aug;51(8):1391-8 [18548227.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):26-34 [18854395.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):559-63 [19033372.001]
  • [Cites] Reprod Sci. 2009 Jan;16(1):7-19 [19144887.001]
  • [Cites] J Nutr. 2009 May;139(5):1002-7 [19321588.001]
  • [Cites] Am J Clin Nutr. 1998 Oct;68(4):854-8 [9771862.001]
  • [Cites] Ann Trop Paediatr. 2006 Mar;26(1):1-16 [16494699.001]
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):1039-44 [18400729.001]
  • [Cites] Photochem Photobiol Sci. 2004 Nov-Dec;3(11-12):1067-70 [15570398.001]
  • [Cites] Osteoporos Int. 2001;12(10):875-9 [11716192.001]
  • [Cites] Gynecol Endocrinol. 2007 Jan;23(1):13-24 [17484507.001]
  • [Cites] Cell Mol Neurobiol. 2010 Mar;30(2):161-71 [19774457.001]
  • [Cites] Arch Dis Child. 2004 Aug;89(8):781-4 [15269083.001]
  • [Cites] J Adolesc Health. 2005 Jul;37(1):75 [15963911.001]
  • [Cites] Diabetologia. 2004 Mar;47(3):451-62 [14758446.001]
  • [Cites] Am J Geriatr Psychiatry. 2006 Dec;14(12):1032-40 [17138809.001]
  • [Cites] Clin Chem. 2009 Jun;55(6):1163-70 [19359534.001]
  • [Cites] Osteoporos Int. 2006;17 (3):433-40 [16362145.001]
  • [Cites] Neurology. 2010 Jan 5;74(1):27-32 [19794127.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2602-8 [16251618.001]
  • [Cites] J Immunol. 2009 Apr 1;182(7):4289-95 [19299728.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):555-63 [1874933.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):67-73 [18984659.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):491-5 [15225826.001]
  • [Cites] Pediatrics. 2009 Mar;123(3):797-803 [19255005.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1099-103 [1328275.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2009 Sep;22(3):188-95 [19073839.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):E53 [11335774.001]
  • [Cites] Nature. 1973 Aug 24;244(5417):515-7 [4621128.001]
  • [Cites] Eur J Endocrinol. 2007 Aug;157(2):225-32 [17656603.001]
  • [Cites] J Trop Pediatr. 2004 Dec;50(6):364-8 [15537725.001]
  • [Cites] Child Care Health Dev. 2008 Mar;34(2):276-8 [18257797.001]
  • [Cites] J Nutr. 2006 Apr;136(4):1130-4 [16549494.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1731-8 [12324490.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3):485-92 [12936933.001]
  • [Cites] Osteoporos Int. 2005 Jan;16(1):109-13 [15175848.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):722-9 [19460797.001]
  • [Cites] Am J Clin Nutr. 2009 Sep;90(3):459-67 [19640956.001]
  • [Cites] Bone. 2009 Sep;45(3):423-6 [19465168.001]
  • [Cites] Am J Clin Nutr. 2007 Jul;86(1):150-8 [17616775.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1748S-51S [15585799.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7 [10902781.001]
  • [Cites] Am J Clin Nutr. 2001 Aug;74(2):206-10 [11470722.001]
  • [Cites] J Pediatr. 2009 Jan;154(1):132-4 [19187735.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):503-11 [18180395.001]
  • (PMID = 28028383.001).
  • [Journal-full-title] Adolescent health, medicine and therapeutics
  • [ISO-abbreviation] Adolesc Health Med Ther
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; Vitamin D / balanced diet / osteomalacia / osteoporosis supplements / rickets
  •  go-up   go-down


96. Raizer JJ, Grimm S, Rice L, Muro K, Chandler J, Tellez C, Mellot AL, Newman S, Nicholas MK, Chamberlain M: A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria required > 18 year of age, KPS > 60, on a non-enzyme inducing anticonvulsant, adequate bone marrow, liver and renal function, and normal urine protein and creatinine.
  • Patients were assessed using Macdonald criteria and continued on trial until tumor progression or toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964646.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Tomasevic Z, Radosevic-Jelic L, Tomasevic ZM, Jelic S, Milovanovic Z: Late relapse in triple negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although triple negative status carries grave prognosis, recent data suggests that it is mostly due to high relapse rate in first 2-3 years following initial diagnosis.
  • Late relapse is determined as contra-lateral BC, loco-regional relapse, or any distant metastases at least 5 years after initial diagnosis of BC.
  • None of these pts had liver, lung, or brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Johnson ED, Tannir NN, Olejeme KA, Logothetis CJ, Jonasch E: Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16096 Background: Renal medullary carcinoma (RMC) is an epithelial malignant tumor arising from collecting duct epithelium.
  • The tumor is almost exclusive to young black patients with the sickle cell hemoglobinopathies, primarily sickle cell trait.
  • This is a rare and highly aggressive tumor that is shown to be most resistant to chemotherapy.
  • Distant sites included bone, liver or lungs.
  • Future studies, including genetic studies on the tumor types are essential to determining the SNP profiles of renal cell carcinoma in black patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Desai K, Bhattacharya S, Srirajaskanthan R, Morgan-Rowe L, Toumpanakis C, Meyer T, Caplin M: Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. J Clin Oncol; 2009 May 20;27(15_suppl):e15650

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour.
  • The most accepted theory relating to development of heart disease is secretion of serotonin (5- hydroxy tryptamine) by the tumour or metastases.
  • METHODS: We analysed retrospectively all patients (n=200) who had metastatic (liver metatstasis) neuroendocrine tumour and carcinoid syndrome with the primary clearly identified within the small bowel or caecum.
  • CONCLUSIONS: Carcinoid heart disease and mesenteric fibrosis (and its effects) are important determinants in morbidity and mortality of patients with midgut neuroendocrine tumour.
  • Although carcinoid heart disease and mesenteric fibrosis are part of the same patho-physiologic process affecting patients with midgut neuroendocrine tumour, the results suggest that progression of these complications is independent of each other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962789.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Cardona Zorrilla AF, Moran T, Reguart N, Porta R, Queralt C, Cardenal F, Carrasco-Chaumel E, Massuti B, Taron M, Rosell R: Characteristics and outcomes of non-small cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response. J Clin Oncol; 2009 May 20;27(15_suppl):8064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 35 pts (63%) were PS ≤2; main metastasis sites were lung (39/71%), bone (21/38%) and liver (10/18%).
  • Mutations in tumor were: 65% DelE19 (Δ746-750), 35% L858R mutation; with 31% and 20% serum detection respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962639.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement